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The increasing frequency and complexity of neonatal care are key
contributors to rising medical costs. Over the past twenty years, neonatal
delivery rates have been increasing and infant mortality rates are improving.
Neonatal care has become very expensive with few applicable clinical guidelines
for care.
ParadigmHealth has developed an integrated, care management structure
termed Systematic Care Management© (SCM). The premise is that by
promoting the most expert and efficient neonatal care, significant reductions in
morbidity will occur, reducing the need for and reduced cost of NICU and
subsequent care. The aim of the study was to determine whether the SCM
process is associated with reductions in neonatal average length of hospital stay.
While inconclusive, the results of this study indicate that the application of
this system is associated with reductions in NICU average lengths of stay for
severity-match neonates. Further experience and analysis is needed to confirm
these findings.
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I. Introduction
High-risk births, which are increasing in frequency and complexity, are
among the leading conditions contributing to the rise in the nation's health care
costs (Lantos, 2001). National statistics reveal that the delivery rates of preterm
and low birthweight (LBW) infants have been slowly increasing over the past 20
years. These infants comprise the major percentage of neonatal intensive care
unit (NICU) admissions (Friedman, Devers, Steiner, & Fox, 2002).
These increasing rates of high-risk births would have been expected to
lead to an increase in neonatal mortality rates. However, continuing
improvements in neonatal intensive care have served to consistently improve
mortality rates across all birth weights (Friedman et aI., 2002). Over the past
twenty years, as the field of neonatal medicine has made profound advances in
knowledge and technology, infant mortality has significantly declined in all
developed nations (Organization for Economic Co-operation and Development,
1999).
It has been reported that, as early as 1990, the net cost (excess of cost
over that of normal birth) of both premature and problem-related births had
reached approximately $5.6 billion per year - an estimated 30/0 of aggregate after
tax corporate profits (Thompson, Goodman, & Little, 2002). Advances in
technologic capabilities are not only making the care of such high-risk births
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more expensive, but confound efforts to produce generally applicable guidelines
for care (Lantos, 2001 ).
The United States has the largest neonatal workforce and hospital
capacity in the world (Pasko & Seidman, 1999). Yet studies suggest that the
relative emphasis toward neonatal intensive care resources is not associated
with better birthweight-specific survival (Goodman & Little, 1998; Fisher & Welch,
1999; Rosenblatt, 1989). In fact, the oversupply of neonatologists and NICUs
may paradoxically lead to less effective care, as the number of severely ill
newborns per neonatologist and per NICU decreases (Phibbs, Bronstein, Buxton,

& Phibbs, 1996). Thompson et al. (2002) suggest that perhaps there is a
threshold where additional neonatal resources yield little measurable benefit.

A Systematic Care Management Method
ParadigmHealth Corporation (ParadigmHealth) has developed through a
modified Delphi technique, an integrated management structure to address these
complex neonatal management issues. This process of care is termed
Systematic Care Management (SCM). Preliminary descriptions of this process
have been published (Carter, Koffler, & McLean, 1999; Cope, Bryant, &
Sundance, 2001; Cope and O'Lear, 1993). The premise of this system is that by
reliably promoting the most expert and most efficient care for these very complex
infants, significant reductions in morbidity will occur, and that these will translate
into reduced need for and reduced cost of NICU and subsequent care (Carter et
aI., 1999).

3

Overview
The objective of this study is to validate the effectiveness of
ParadigmHealth's systematic care management (SCM) model in reducing the
average length of stay for infants in an NICU. The SCM model encompasses a
process specifically designed to address the challenge of extremely complex
medical problems (Cope & Sundance, 1995). SCM represents
comprehensiveness, coordinated communication, medical service integration,
and supplements the basic principles of traditional case management with fiscal
accountability and the development and use of evidence-based, data-driven
clinical pathways (Cope & Sundance, 1995). It has found acceptance and utility

by providers, patients, and payers in a wide range of clinical conditions, including
high-risk neonates (Cope, Bryant et aI., 2001).

Background and Need
Enormous resources are invested in health care in the United States. In
1998, national health care expenditures were greater than $1.1 trillion (Levit et
aI., 2000). This 14.10/0 of the national gross domestic product is demonstrated in
the average of $5,035 per person that Americans spend on health care each
year, higher than in any other country in the world (Mcintosh, 2002). The
excessive growth in the costs and complexity of health care in the United States
is expected to continue, with health care expenditures projected to reach $2.3
trillion dollars (15.5% to 16.60/0 of GDP) by 2008 (Longest, 2001). These
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increases are occurring concurrently with significant breakdowns in the
organization and delivery of health care, resulting in a health care delivery
system that lacks appropriate clinical and administrative information systems
(Richardson, 2001).
The American public has placed the state of health care today as a
primary domestic concern (Donelan, Blendon, Schoen, Davis, & Binns, 1999).
Few are happy with the system as it currently operates. The basic issues
underlying efforts to improve the U.S. health care system are concerned mainly
with reducing costs, increasing access to health care (especially for the
uninsured or underinsured), and further improving and maintaining quality health
care (Geyman, 2002; Longest, 2001; Sultz & Young, 1997). In recent years,
improving the quality of U.S. health care has become a national focus with the
Institute of Medicine releasing a sUbstantive report outlining a twelve-point
process for such improvement (Kahn, Corrigan & Donaldson, 2001). The central
theme of this report, Crossing the Quality Chasm: A New Health System for the
21

st

Century, is the belief that there must be a fundamental restructuring of our

healthcare delivery system with a focus on evidence-based medicine and
outcomes (Kohn et aI., 2001; Geyman, 2002). Yet reliable and timely information
about health care and its outcomes is lacking for even the most basic of health
conditions (Mcintosh, 2002).
Managed care has introduced multiple financial and management
strategies with the intent of restraining costs while maintaining appropriate quality
of care. These include the following: price controls (limiting reimbursement for

5

individuals or aggregate services}, diagnosis related group reimbursement or
"DRGs" (provider reimbursement based upon a specific diagnostic code),
preferred provider organizations or "PPOs" (reduced rates from contracted
providers in return for an expected increase in volume), capitation (provider
reimbursement based upon a "per member per month" rate of payment
regardless of services provided), peer review (physician/medical expert review of
services provided), utilization review or "UR" (external review of need for ongoing
prescribed services), and case management (primarily a nurse-oriented
utilization review or cost containment) (Miller & Luft, 1997). While these
strategies have had some positive effect, both consumers and providers of care
consistently view them as heavy-handed, arbitrary, and intrusive (Cope, Bryant et
aI., 2001; Mcintosh, 2002).
The short-term savings (reflected in reduced premiums for the next annual
insurance contract cycle) have become the primary determinant of success for
health plans. It has been documented that neither the purchasers nor the
providers of health care have developed methods of financing or service delivery
which successfully lead to appropriate and affordable high quality care for
patients with complex medical conditions (Cope, Bryant et aI., 2001; Sandy &
Gibson, 1996; Sutton & Dejong, 1998; Tanenbaum & Hurely, 1995). In addition,
despite numerous attempts to manage health care expenditures, costs continue
to rise at double digit rates (Ginsberg, 1999; Smith, Freeland, Heffler, &
McKusick, 1998), and morbidity continues to escalate secondary to unnecessary,
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inadequate, inexpert, or inefficient care (Gray & Fields, 1989; Jenkins, 2000;
Mechanic, 1997; Schwartz, 1998).

Purpose of the Study
This study will be the first analysis of ParadigmHealth's neonatal
management system, referred to as Systematic Care Management. The study
will encompass three years of ParadigmHealth's experience with this population
of high-risk births (1998, 1999, and 2000).

Its purpose is to demonstrate that

this process of management is associated with significant reductions in the
average length of stay (ALaS) of complex, high-risk neonates during their initial
NICU hospitalization.

Significance of the Study
Over the past few decades, neonatal intensive care has confronted,
clashed with, and in many ways adapted our collective medical consciousness.
Through advances in technology and science, physicians have developed
methods to save the lives of an entire population of infants who once were
thought too small or fragile to survive (Grumbach, 2002; Lantos, 2001). Neonatal
intensive care has changed the way we think about what infants demand from
our society and about what we, collectively, owe to them. It has changed the
way physicians, hospitals, and academic medical centers conceptualize their
missions. In many cases, neonatal intensive care has become the centerpiece of
tertiary care pediatrics (Friedman, Devers, Steiner, & Fox, 2002; Lantos, 2001).
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NICUs have become not just the focus of pediatric scholarly work but also the
economic lifeblood of academic medical centers (Gleid & Gnanasekaran, 1996).
Nationally, about 53,000 infants are born with a birthweight of less than three
pounds. At today's survival rates, these infants will account for 2.1 million
hospital bed days. Just ten years ago survival rates were 30-50% lower (and
would have accounted for only 1.6 million hospital bed days). As a result, NICUs
have become the economic engine that keeps children's hospitals running
(Friedman et aI., 2002; Goodman, Fisher et aI., 2002; Lantos, 2001).
Buoyed with this positive affirmation of improved mortality, the
practitioners of neonatal intensive care have been somewhat sheltered from the
cost-containment methods of managed care (Friedman et aI., 2002; Gerber,
Dobrez, & Bidetti, 2001). It is believed, however, that the delivery of neonatal
care, as with areas of adult intensive care, remains below obtainable levels of
appropriate lengths of stay, cost, and customer value.

NICUs are economically

successful because they are medically successful. Given the costly nature of
care for these critically ill infants, payer organizations continue to search for ways
to manage these costs more effectively (Ginsburg & Ostow, 1997). This study
will seek evidence that SCM is an effective method for managing these costs by
reducing the mean length of stay for infants admitted to the NICU.
In an era of cost containment and accountability for quality of care, any
connection between experience and patient outcome has far-reaching
implications for patients, payers, and governmental agencies (Brinkmeyer,
Brinkmeyer, Wennberg, & Young, 2000; Freund, Rossiter, & Fox, 1989; Jameson
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& Wehr, 1993; Jencks, 1997; Musci, Esslinger, & Kornhauser, 2001). Despite

compelling evidence of the value of highly specialized neonatal intensive care
units, questions remain about the proliferation of these units and the clinical
processes that determine length of stay (Chenoweth, 2001; CIGNA HealthCare,
1992; Grumbach, 2002). This study will examine whether SCM is also effective
in reducing the variability that exists (Musci et aI., 2001) in NICU lengths of stay.

Specific Aims

This study had two (2) specific goals:
1. To determine whether the SCM process of management is associated
with significant reductions in the average length of stay (ALOS) of highrisk neonates during their initial NICU hospitalization.
2. To determine whether SCM is effective in reducing the range of NICU
lengths of stay (LOS).

Research Hypotheses

The study had two (2) primary hypotheses:
H1:

There

is

evidence

that

ParadigmHealth's

Systematic

Care

Management (SCM) process results in a reduction in NICU average
length of stay (ALOS).
H2:

There is evidence that the SCM process reduces the range of
patient length of stay) in the high-risk neonate (NICU) population.
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The balance of this manuscript will present a review of the literature in
chapter two. A detailed discussion of the project's methodology is found in
chapter three. Chapter four contains the results of the analysis process. A
discussion of the findings, conclusions, applications, limitations and lessons
observed during the project are presented in chapter five.

II. Literature Review

Introduction
The US health care system has a long-standing reputation as being one of
the most advanced and sophisticated health care systems in the world
(Browning, 1992; Sultz & Young, 1997). The desire of patients and physicians
for increasingly more advanced (and costly) health care, coupled with the
willingness of third-party payers to meet the costs of providing it, has generated
ample encouragement for speedy technological advancement (Weisbrod, 1991).
These advances in biomedical science have largely propelled the evolution of the
nation's health care system as well as the explosion in the costs of providing
such sophisticated care.
The costs of providing health care in the United States have increased
dramatically, from $27.1 billion in 1960 to $884.2 billion in 1993 (Ayres, 1996;
Sultz & Young, 1997). Longest (2001) found that Americans spent more than $1
trillion in pursuit of health in 1997 and expects this total to rise to $1.5 trillion this
year. Today, the United States spends 40% more per capita on health care than
any other Western industrialized nation (Mcintosh, 2002; Guyer, Freedman,
Strobino, & Sondik, 2000).
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Our health care industry continues to be one of the largest, most diverse,
and fastest growing industries in the country (Geyman, 2002). It comprised one
seventh of the US economy in 1998 (Mcintosh, 2002). The national health care
expenditures have risen faster than most other components of the US economy
(Browning, 1992). This growth in the costs and complexity of health care in the
United States is expected to continue with health care expenditures projected to
reach $2.3 trillion (15.50/0 to 16.60/0 of GDP) by 2008 and $2.8 trillion (17% of
GDP) by 2011 (eMS, 2002). These increases are occurring concurrently with
significant breakdowns in the organization and delivery of health care, resulting in
a health care delivery system that lacks appropriate clinical and administrative
information systems (Richardson, 2001).

The Premise of Managed Care
Managed care describes a collection of healthplan activities designed to
reduce the high levels of utilization and spending that accompanied unfettered
fee-for-service medicine (Baker & Phibbs, 2002; Zwanziger & Melnick, 1996).
The activities that fall under the rubric of managed care can be loosely placed in
three groups. First, managed care plans attempt to alter financial incentives.
Second, managed care plans often assert control over treatment decisions.
Third, managed care plans often search for a set of physicians and hospitals with
whom they desire to contract, negotiate with these providers, and then restrict
their members to use the chosen providers (Zwanziger & Melnick, 1996). The
belief on the part of the plans appears often to be that fee-for-service medicine
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was characterized by excessive use of expensive tests and procedures, and they
have frequently focused their attention on curbing the use of these services and
reducing the amount they pay for them (Miller and Luft, 1997).
An effective managed care system is one that has processes in place to
evaluate patients' short-term and long-term needs and apply the appropriate
model of care for each subgroup of its population (Zwanziger & Melnick, 1996).
It is particularly important for a managed care system to be set up to plan
carefully for the health care requirements of persons with catastrophic injuries or
conditions, given the inevitably high cost of their care and their need for ancillary
support services and long-term maintenance. However, our society's
understanding of how well managed care has succeeded in planning and
delivering the care of persons with catastrophic injuries and conditions requiring
long-term oversight is extremely limited. For persons with special health care
needs requiring long-term services, there is virtually no research evaluating the
impact of managed care on long-term health (Applebaum & Mayberry, 1996;
Berkowitz & Halfon, 1992).
The published literature on managed care gives a mixed impression of its
effectiveness overall in managing health care costs, improving access and
quality of services and establishing equitable priorities for allocating health care
resources (Freund et aI., 1989). On the plus side, cost management is facilitated
by managed care's use of utilization controls (England & Muchnick-Baku, 1997)
and provider reimbursement methodologies that offer incentives for health care
providers to conserve resources. Managed care has been shown to provide
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increased access to ancillary services, more extensive coverage of home health
care and outpatient mental health services and more of a focus on case
management compared with fee-far-service arrangements (Fox, Wicks, &
Newacheck, 1993).
Managed care organizations, while providing increased access to certain
services, may place limits on the quantity or duration of services (Geyman,
2002). The traditional managed care approach to cost containment emphasizes
administrative procedures such as utilization review and pre-certification. The
evidence indicates that managed care can increase service efficiency, reduce
utilization of emergency rooms and inpatient services, decrease out-of-pocket
costs, all with little effect on quality of care overall for the enrolled population
compared with fee-far-service plans (Perrin, Newacheck & Pless, 1993).
However, a number of authors have argued that such administrative costconstraining measures do have a deleterious effect on health status and
outcomes and turn out to be secondarily cost-increasing as a result (Jameson &
Wehr, 1993; Nelson, Brown, Gold, Ciemnecki, & Docteur, 1997).
Before the advent of managed care, health insurers typically paid health
care providers using fee-far-service reimbursement, exercising little oversight of
treatment decisions made by patients and their physicians (Silver, 1997; Spitz,
1987). Over the past fifteen years, multiple financial and management strategies
have been developed with the intent of restraining costs while maintaining
appropriate quality of care (Altemeir, 1995). Examples include price controls
(limiting reimbursement for individuals or aggregate services), diagnosis-related
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group reimbursement or DRGs (provider reimbursement based upon a specific
diagnostic code), preferred provider organizations or PPOs (reduced rates from
contracted providers in return for an expected increase in volume), capitation
(provider reimbursement based upon a "per member per month" rate of payment
regardless of services provided) (Zwanziger & Melnick, 1996), peer review
(physician/medical expert review of services provided), utilization review or UR
(external review of need for ongoing prescribed services), and case management
(primarily a nurse UR cost containment function with the nurse, at times, not
having insufficient expertise or power to significantly influence the care process)
(Cope, Bryant, et aI., 2001; Horn, Sharkey, Tracy, et aI., 1996).
While these strategies have had some positive effect, the previously
mentioned methodologies are consistently viewed by both consumers and
providers of care as heavy-handed, arbitrary, and intrusive, such that short-term
savings (reflected in reduced premiums for the next annual insurance contract
cycle) have become the primary determinant of success for health plans (Mark &
Mueller, 1996). This should not come as a surprise since, dating back to 1912,
five major attempts to reform the U.S. health care system have all failed
(Mcintosh, 2002).

Populations with special needs. There is evidence that managed care
organizations particularly tend to under-serve certain subsets of patients.
Vulnerable populations, such as the elderly, non-elderly disabled, persons with
functional impairments, and persons with debilitating conditions, have had
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documented difficulties obtaining access to necessary services under managed
care plans (Miller & Luft 1997; Nelson et aI., 1996; Petrou, Sach, & Davidson,
2001). Plans may limit or deny coverage if they determine that a service is not
medically necessary, experimental or investigative (Rosenblatt, 1989; Sandy &
Gibson, 1996).
Some health maintenance organizations may be reluctant to pay for
intensive early intervention or the kinds of cross disciplinary or specialty care that
persons with chronic conditions require (Altemeir, 1995). There is a concern
among some managed care organizations that if they do incorporate a broad
continuum of services in their plan, they may attract a disproportionate share of
persons with special health care needs (Altermeir, 1995). The tendency of
managed care organizations to under-serve or even avoid enrollment of highcost populations who require disproportionately more services than the general
population is a process known as adverse selection (Horn, Sharkey, Tracy et aI.,
1996; Luft & Miller 1988).
In particular, it has been documented that neither the purchasers nor the
providers of health care have developed methods of financial or service delivery
managernent which successfully lead to appropriate and affordable high quality
care for patients with complex chronic or disabling conditions. These conditions
include catastrophic injuries or medical events such as acquired brain injuries,
spinal cord injuries, severe multiple trauma, severe burns, and significantly
premature infants (Cope, Bryant et aI., 2001; Sandy & Gibson, 1996; Sutton &
Dejong, 1998; Tanenbaum & Hurely, 1996). In addition, despite many of these
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management attempts, costs continue to rise at double digit rates (Ginsburg,
1999), and morbidity continues to escalate secondary to unnecessary,
inadequate, inexpert, or inefficient care (Gray & Fields, 1989; Horn, Sharkey,
Tracy et aI., 1996; Jenkins, 2000; Mechanic, 1997; Schwartz, 1998).

Caring for high-cost populations. High-cost populations, although they
represent a minority of patients in today's health care environment, incur a
disproportionate share of health care expenditures (Hobar, Badger, Lewit,
Rogowski, & Shiono, 1997; Lessaris, Annibale, Southgate, Hulsey, & Ohning,
2002). Such populations tend to require a complex set of care resources,
extending across the full continuum of care and over a long-term time horizon.
Today's health care organizations are particularly challenged to achieve their
fundamental objectives for those sectors of the population that incur the highest
costs (Thompson et aI., 2002). Such patients include those with catastrophic
injuries, the severely chronically ill, those in the last year of life, and those born
prematurely with very low birth weights (neonate). Many of these vulnerable
groups are excluded from or inadequately integrated into managed care delivery
systems, and their care historically has been fragmented and poorly coordinated
(Lewit, Baker, Corman, & Shino, 1995; Miller & Luff, 1997).
In view of the mixed evidence on managed care, it is not surprising that
there is a growing concern in the policy community about maintaining access to
appropriate care while controlling costs for critically ill populations (Sandy &
Gibson, 1996; Stolz & McCormick, 1998). Rather than stirring up a backlash

17

against managed care, however, a more productive response is to develop a
philosophy and strategy of care management that supports and improves the
effectiveness of managed care (Scott, 2000; Silver, 1997; Tanenbaum, 1994).

Neonatal Intensive Care
Currently, one of every nine births in the U.S. results in an admission to
neonatal intensive care (Guyer et aI., 2000). Of the 3.8 million births in the U.S.
annually almost 400,000 infants are treated in NICU, at a cost of over $9 billion
nationally (Musci et aI., 2001) and at an average individual cost of more than
$250,000 (Stolz & McCormick, 1998).
Since 1990, the United States has seen a 32% decrease in infant
mortality, from 10.2 to 6.9 deaths per 1,000 live births (UnitedHealth Foundation,
2002). Even with these improvements, the United States ranks 27th among
developed countries in its infant mortality rate, just above Hungary and Slovenia
(Eberhardt, Ingram, & Makuc, 2001). While recent advances in the technology
and care delivery have improved the long and short-term outcomes of this
population (Fawke & Mcintyre, 2002), the neonatal period continues to have the
highest death rate in childhood (Guyer et aI., 2000).
The intensity of caring for this complex patient population has been
accompanied by concerns about cost effectiveness of high technology NICU
environments (Friedman et aI., 2002; Lorenz & Jetton, 2001). In addition,
concerns over racial and economic disparities in care have been documented
(Demissie et aI., 2001; Gleid & Gnanasekaran, 1996; Rowland, Hogue, &
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Vasquez, 2002).

Others have questioned the eventual quality of life (Meadow,

Frain et aI., 2002; Schwartz, 1996) and potential long-term health consequences
for NICU survivors (Lewit et aI., 1995; Petrou et aI., 2001; Siomin, Patel,
Ruttimann, & Pollack, 2000).

The neonatal intensive care unit defined. Medical care for low birthweight
infants is provided in neonatal intensive care units (NICUs) in hospitals with
obstetric services or in children's hospitals. According to the American Academy
of Pediatrics (1977) services in NICUs include constant nursing and continuous
cardiopulmonary and other support for severely ill infants as well as other
specialty services and technology. Generally, this care is provided by
pediatricians with advanced training in neonatology, specialized nurses, and
other specialized staff. Any given NICU contains a range of equipment and
service capabilities that collectively represent the NICU technology (Baker &
Phibbs, 2002). Not all birth hospitals have NICUs; infants who are born outside
of NICU hospitals and who need such services are usually transferred to the
nearest NICU facility (Bode, O'Shea, Metzguer, & Stiles, 2001; Chang & Klitzner,
2002; McCormick & Richardson, 1995).

The classification of neonatal intensive care units. Perinatal health care
systems have evolved to deliver infants of pregnant women in health care
facilities that range from level I (without neonatal intensive care units or high-risk
I

obstetric and pediatric staff) to level III (fully equipped, tertiary NICU facilities).
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Between these two extremes are the level II units, often referred to as mid-level
or "community" NICUs (Goodman, Fisher et aI., 2001). These units provide
some of the advanced services of a level III, but not all. These mid-level units
typically do not have the staff and equipment for treating rare and very serious
cases or the staff and equipment to support complex neonatal surgeries (Baker &
Phibbs, 2002; McCormick, Shapiro, & Starfield, 1985).
Hospitals that host planned deliveries are equipped with a well-baby
nursery, containing basic equipment for the care of healthy newborns and those
with minor medical problems. Hospitals that offer only this level of service have
no NICU and their infant care units are classed as level I nurseries (Cifuentes et
aI., 2002).

Infants delivered in a level III hospital have access to state-of-the-art

medical care that both increases their survival chances and reduces risk of longterm developmental and physical problems. Often referred to as regional or
tertiary NICUs, these units provide a full range of specialized neonatal care for
the most seriously ill newborns, including long-term mechanical ventilation,
subspecialty consultants, and surgeries (Hein & Lofgren, 1999; Howell,
Richardson, Ginsburg, & Foot, 2002).
Although they are expensive, NICUs can have a powerful impact on the
prognosis for high-risk infants, substantially lowering mortality rates for severely
ill newborns and improving non-mortality outcomes for other sick infants
(Williams & Chen, 1982). Research has shown that infants who are cared for in
NICUs have better rates of survival than those who are not, after infant size and
i

gestation are controlled for (Howell et aI., 2002; Richardson, Gray, Gartman,
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Purlsey, & McCormick, 1998). Another body of research has generally shown
that infants born in higher-volume NICUs have better survival than those born in
lower-volume facilities (Mayfield, Rosenblatt, Baldwin, Chu, & Logerfo, 1995;
Phibbs, Bronstein et aI., 1998; Rosenthall, Harper, Quinn, & Cooper, 1997;
Sanderson, Sappenfield, Jespersen, Liu, & Baker, 2000; Sankaran et aI., 2002).

Relationship between length of stay and NICU costs. For some time
researchers and practitioners have noted that there appears to be a complex,
non-linear, inverse and temporal relationship between a neonatal intensive care
patient's day of life and the quantity of hospital resources required to provide
their care (Doyle, Murton, & Kitchen, 1988; Kaufman & Shepard, 1982). There
are many causes for this phenomenon. In studies of costs in NICU, researchers
have found that there is significant variability in cost of care among neonates in
NICU (Lorenz & Jetton, 2001). These studies have attributed this variability to
improved access and use of advanced technologies extending survival and
length of stay (Behnke, Eyler, Conlon, Casanova, & Woods, 1997; Khoshnood et
aI., 1996) rather than to individual practitioner (Perlstein, Atherton, Donovan,
Richardson, & Kotagal, 1997; Schulman, Lucchese, & Sullivan, 1995) or
organizational practices (Rogowski, Horbar et aI., 2001). In addition to length of
stay, important indicators to the ultimate costs of NICU care were the presence of
mechanical ventilation, parenteral nutrition, and advanced technology (Tyson &
KennedYJ/2002). It should be noted that researchers have demonstrated that
over 80% of the dollars spent in NICU will be spent on infants who ultimately
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survive, compared to adult ICUs where less than 50% of all dollars will be spent
on survivors (Meadow, Kim et aI., 2002; Mehta et aI., 2000).
Since the later 1990's, the use of clinical practice protocols and guidelines
as the standards for case management in neonatal care has provided an
opportunity to study the effect of systematic care protocols in reducing the
variability in NICU settings (Merritt, Palmer, Bergman, & Shiono, 1997). Several
of these studies indicate that the use of clinical practice guidelines can directly
affect newborn and NICU length of stay (Jones, 1994; Neidig, Megel, & Koehler,
1992; Turley, Tyndall, & Rage, 1994), resulting in improved costs of care. The
use of triage protocols in NICU contributed to reducing cost and length of stay by
affecting not only the severity of illness but also acknowledging non-medical
markers of resource consumption and unit structure (Zupancic & Richardson,
1998).
In the mid-1990's assessment of neonatal intensive care led to the
development of economic models for determining cost of care and length of stay
using financial and clinical data from the neonatal care experience (McCormick &
Richardson, 1998; Phibbs, Phibbs, Pomerance, & Williams, 1986; Thomas &
Ashcraft, 1991). The publication of these models ultimately resulted in the
implementation of the APR-DRG system to both assist in differentiating risk in
neonatal care and more fairly adjust for the complexity and variability of the
neonatal care experience.
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The Evolution of Evidence-Based Medicine
The practice of medicine has long been recognized as a subtle mixture of
art and science. This tenuous blend of "head and heart" has historically sparred
debate as to the most correct approach in delivering patient care. Until recently,
few tools have existed to identify superior treatment methods in medicine. As
new tools and techniques have been developed to help practitioners better
understand the optimal treatment of patients, medicine has begun a notable
move toward an exact science (Sackett, Richardson, Rosenberg, & Haynes,
1997). The past decade has shown tremendous and exciting growth in the
development of this science, known today as evidence-based medicine (EBM)
(Eisenberg, 1999).
Over the past five years, EBM has clearly advanced medical knowledge.
While many in the health care community have welcomed this move forward,
some foresee potential erosion of individual professional autonomy and the loss
of the art of medicine (Roscoff, 2001). Clinicians who have historically enjoyed
wide latitude to exercise personal discretion in choosing treatments for their
patients now may feel increasing pressure to conform to established norms of
patient care (Hirshfield, 1991) as more becomes known about the "most correct"
way to treat a particular medical condition (Tanenbaum, 1994).
In an environment supportive of EBM, a clinician might more readily be
held accountable for a poor patient outcome if that outcome can be attributed to
deviation from an EBM-prescribed treatment approach (Hyams, Shapiro, &
Brennan, 1996). As a result, EBM is seen by some medical professionals as

23

packing a one-two punch: erosion of autonomy in a treatment choice
accompanied by greater risk of liability after the fact (Felsenthan, 1994). This risk
of potential liability is magnified as legal uses and interpretations of EBM and
other science-based medical evidence have potential to diverge from initial
interpretation of that evidence by the medical and health care researchers who
produced it to the practitioners and health plans that use the findings in making
clinical decisions and policies (Havighurst et aI., 2001).

Definition of evidence-based medicine. EBM is defined as the
conscientious, explicit and judicious use of current best evidence in making
decisions about the care of individual patients (Field & Lohr, 1990; Sackett et aI.,
1997). Emphasizing structured and critical examination of medical research to
determine clinical effectiveness, EBM challenges consensus-based judgments
and applies critical assessment to determine methodologically sound evidence
and favorable clinical outcomes (Belkin, 1997).
Physicians are encouraged to practice "evidence-based medicine," so that
clinical decisions would be based upon a foundation of solid science, rigorous
epidemiologic methods and published peer-reviewed findings. Moreover, there is
a distinction between "efficacy," evidence of an effect under ideal conditions,
such as in double-blind, randomized controlled trials, and "effectiveness,"
evidence of what actually works in clinical practice. Although this distinction is
subtle, it is important for all users of evidence to understand, especially those
who seek to use EBM to define medical quality (Roscoff, 2001).
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Clinical practice guidelines - the origin of EBM. EBM has impacted
medical practice largely through the development, dissemination, and use of
clinical practice guidelines (Eisenberg, 1999). The Institute of Medicine's widely
cited 1990 report defines clinical practice guidelines as systematically developed
statements to assist practitioner and patient decisions about appropriate health
care for specific clinical circumstances (Field & Lohr, 1990). These statements
are used to guide practitioners undertaking treatment of vari0l:'s conditions and to
help hospitals, third-party payers, regulatory bodies and practitioners determine
whether care given in a particular instance was adequate and appropriate
(Brennan, 1991).
The Institute of Medicine's (10M) Committee on Clinical Practice
Guidelines identified the attributes of good clinical practice guidelines almost a
decade ago. The 10M evaluation instrument has been refined in the United
Kingdom and Europe over the past eight years, and a multinational study of
evaluative criteria for clinical practice guidelines is ongoing (Roscoff, 2001).
Worldwide systems used in formulating guidelines differ in at least five respects,
including methods for identifying, appraising, and ranking relevant research
evidence; models for integrating indirect evidence; methods for incorporating
experience and opinion; models for evaluating potential harm, cost and value;
and sponsorship (Daly, 1995). Consequently, most guidelines are a complex
amalgam of clinical experience, expert opinion and research evidence
(Havighurst et aI., 2001).
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Clinical practice guidelines are being developed through two distinct
research techniques. The first class of clinical practice guidelines is developed
through a consensus process where the treatment recommendations are a
consolidation of reality-based inductive thought, contemporary belief and day-today medical practice. The second class of guidelines is generated through more
deductive and rigorous analysis of empiric outcomes data. While more
technically correct and research based, this latter class of clinical practice
guidelines, when first disseminated to the medical community, is much less likely
to reflect current professional practice (Sackett & Guyatt, 1992) than it is
representative of an ideal care process.
Guidelines, when used to infer clinical quality, most often apply to the
general and not the particular (Daly, 1995). Following evidence-based guidelines
does not always assure good outcomes, just as diverging from guidelines does
not always signal poor care (Field & Lohr, 1990). Each requires extrapolation to
individual circumstance (Brennan, 1991).

Medical standards of care. Unlike a guideline, which is a recommendation
for best practice, medical standards are known practices that are medically
necessary and services that any health care practitioner under any circumstance
would be required to render (Havighurst et aI., 2001). Evidence-based guidelines
focusing on single conditions likely will enhance, but not solely determine,
standards of medical care in the United States. As well, research evidence alone
will invariably be inadequate to establish medical standards, as standards require
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priority setting based on cost and value judgments (Field & Lohr, 1990; Sackett
et aI., 1997).

Changing medical practice in response to EBM. The process of changing
medical practice in response to EBM is gradual and fragmented (Eddy, 1996;
Tanenbaum, 1994). In the short run, physicians' decisions are not likely to be
greatly influenced by outcomes research. Physicians are inclined to be
distrustful of such studies and the conclusions drawn from them (Tanenbaum,
1994). Research evidence can be ambiguous and requires interpretation and
judicious weighting of its significance (Eisenberg, 1999). Even when physicians
accept research findings as accurate in general, they tend to find reasons to
believe that their particular patient is atypical and, therefore, merits treatment
different from that which might normally be indicated by the study findings
(Selkin, 1997; Matthews, 1999; Tanenbaum, 1994).
Despite physicians' assumption that their practice is rooted in empirical
science, the past three decades have produced incontrovertible evidence that
clinical practice deviates from research-based recommendations (Eddy, 1996).
There is sufficient evidence to suggest that most clinicians' practices do not
reflect the principles of evidence-based medicine but rather are based upon
tradition, their most recent experience, what they learned years ago in medical
school or what they have heard from their peers (Eisenberg, 1999). The average
physician is said to read scientific journals approximately two hours per week,
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and most are likely overwhelmed by the volume of material confronting them on a
daily basis (Tannenbaum, 1994).
Recent emphasis on evidence-based medicine and information systems
has begun to promote the use of evidence in medical education programs
(Sackett & Guyatt, 1992). Medical education as a whole now recognizes that no
physician can know all the literature, but that through evidence-based practice
physicians can judge the treatment and diagnostic options for the patient at hand.
Thus the culture of medical education is moving toward building a base for
practice grounded in science (Eisenberg, 1999). Practicing evidence-based
medicine is not easy. No clinician alone can absorb and synthesize the vast
amount of literature available, make judgments on its quality, and translate all
findings into their clinical practice (Shuman, 2001).
Many physicians decry the spread of clinical practice guidelines (and other
forms of EBM) as the advent of "cookbook medicine," having the potential to
lower the quality of health care by subordinating and subverting professional skill
and judgment (Tanenbaum, 1994). Without question, today's clinical practice
guidelines should not be viewed as conclusive evidence of the standard of care.
No single authoritative guideline for medical conditions exists. For many
conditions, there are multiple, and sometimes conflicting guidelines. As case in
point, the American Cancer Society recommends yearly mammography, and the
American College of Obstetricians and Gynecologists recommends "regular"
mammography without specifying frequency_ Which of the two should be viewed
as "more expert" (Roscoff, 2001; Eisenberg, 1999)? Physicians will have to
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engage in a process of deciding, when guidelines conflict on a material point,
which one to treat as the more authoritative. The likely outcome is that,
assuming each guideline meets minimum qualifications, both will be considered
acceptable and medical practitioners will be left to choose between them perhaps with adequate wisdom, perhaps not (Anderson, Hall, & Smith, 1998).

Creating A New Model of Care
Managed care, case management, and disease (or disease state)
management are all terms that refer to care delivery systems developed to
manage high-cost patients or conditions. However, these terms, especially
disease management, have been applied so loosely and to such a variety of
activities over the years that they have lost much of their meaning. While these
terms are often used interchangeably, they denote different methodological
approaches to health care delivery and derive from different perspectives.
Managed care is a system of care focused on controlling the use of health
care resources (Gardner & Scheffler, 1988). The term case management, in
contrast, has been increasingly used to denote a patient care management
mechanism that coordinates the complex health needs of individuals in an
increasingly fragmented health care delivery system (Berkowitz & Halfon, 1992).
The American Nurse Association defines case management as health
assessment and planning, procurement, delivery coordination, and monitoring to
ensure that the multiple needs of the client are met (Kurec, 1996).

29

Disease or disease state management differs in its approach from both
managed care and case management. Disease management takes a systems
approach to the management of moderately costly, relatively high prevalence
chronic diseases, including such conditions as diabetes, cancer heart disease,
and asthma. However, systematic care management, while an evolution of
disease management and case management, is distinguished from both
approaches in that it is a more comprehensive, collaborative, evidence-based
and fiscally accountable model, for ongoing management of catastrophic injuries
and conditions (Cope, Bryant et aI., 2001).

Systematic Care Management (SCM)
In response to the evident deficiencies of early management efforts as
well as the enormous costs associated with both short- and long-term treatment
of complex conditions, it is critical that

a new management system be

implemented that incorporates adequate clinical data capture and analysis,
coupled with empirically derived managed principles (including but not limited to
EBM). Such a system must also recognize the limitation of a purely data and
science driven management approach, and integrate these where necessary with
a structured approach based upon consensus expert clinical judgment. For the
past decade, such a system (referred to as systematic care management) has
been in development at ParadigmHealth (Cope, Bryant et aI., 2001).
Insurers, employers, and managed care firms contract with
ParadigmHealth to facilitate the care management process for catastrophic and
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medically complex conditions (Carter et aI., 1999). The objectives are to reduce
costly deviations in care, apply proven methods of treatment, enhance patient
outcomes, and import expertise when care is being delivered in more remote
settings using a collaborative, physician expert model (Cope, Nathan et aI.,
1995).

SCM defined. Systematic care management (SCM) is a process of clinical
and financial management of high-cost patients that focuses on
comprehensiveness, coordination and integration (Cope, Bryant et aI., 2001).
SCM supplements the basic principles of case management with fiscal
accountability and the development and use of evidence-based, data-driven
clinical pathways. Unlike traditional case management, SCM places value on the
prevention of future adverse events by managing problems in a timely manner
and slowing the rate of decline of patients with chronic conditions (Carter et aI.,
1999).
The goal of SCM is to ensure that each catastrophically injured or
chronically ill patient receives the most appropriate medical care required,
allowing him or her to achieve the highest feasible clinical recovery, while at the
same time minimizing the expenditure of inexpert, unnecessary or ineffective
medical resources (Cope & O'Lear, 1993). There is now growing recognition that
achieving these results requires integrated clinical and financial care
management based on collaborative relationships, data-driven processes and
fiscal accountability (Friedman et aI., 2002; Geyman, 2002). It has been
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suggested that achievement of both clinical and financial care goals are
enhanced by some degree of risk transfer to the provider to ensure incentive
alignment (Horn, Sharkey, Tracy et aI., 1996; Kurek, 1996; Miller & Luft, 1997.

Elements of SCM. The SCM process is both data and outcome driven and
relies on clinical experts to apply a structured management approach across all
cases (Cope, Nathan et aI., 1995). The principles that make this model of care
management uniquely suited for the medically complex population follow:

1. The provision of clinical expertise to col/aborative/y assist in the care
process. Clinicians who are expert in the field are best suited to understand
the clinical complexities of care for high-risk neonates (Cope & O'Lear, 1993).
Using this logic, ParadigmHealth identifies and retains expert neonatologists,
neonatal nurse practitioners, and neonatal clinical consultants to work as a
team in managing cases. These clinicians collect, analyze and interpret the
data and then work collaboratively with the attending physicians and nurses
who are treating the infant to develop an effective and efficient care path.
The Paradigm neonatal team provides support, education and consultation to
the parents of the infant to assure that they are fully apprised of the care
being provided and to assist them in preparation for discharge home. The
team provides ongoing support to the family during the critical initial period at
home post discharge from the NICU. On occasion, when clinically indicated,
this core team is expanded to include pediatric surgeons, cardiologists or
other subspecialties to consult with the ParadigmHealth team to assure
optimal outcome achievement (Carter et aI., 1999; McLean et aI., 2002).
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2. A data system that aggregates detailed relevant clinical and financial
information to allow correlations of clinical conditions, medical management
and financial and clinical outcomes. The Paradigm database and data

collection tools are crucial to the prediction and management process and the
care path development necessary to achieve a successful outcome. The
clinical database has been built in collaboration with MillimanUSA and is
comprised of approximately 320,000 neonatal cases from throughout the
United States. The patients in the database include those managed by
Paradigm as well as cases not managed by Paradigm (utilized for comparison
purposes). The information included in the database ranges from discrete
physiological measures to ICD-9 diagnosis and procedure codes, as well as
detailed billed and paid NICU cost data (Cope, Bryant et aJ., 2001).

3. Structured management processes which assure reliable and efficient
application of clinical knowledge and care across multiple and extended
clinical settings and over prolonged periods of time. These processes include

a. The establishment of a specific outcome to be achieved in each case.
For neonates, the outcome is successful discharge from the NICU with
a minimum of 30 days of stability within the home environment;
b. Standardized data collection tools that are utilized for all cases,
therefore, the same data are available across all cases irrespective of
diagnoses and severity;
c. A proprietary Levels of Acuity system that is applied across all levels of
severity of neonates. This system has five levels of care ranging from
Extreme Care or ECMO to Continuing Care. It delineates the criteria
that must be met for an infant to be assigned to a particular acuity level
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and also specifies the criteria the infant must achieve to move from
one level of acuity to the next;
d. Structured discharge criteria; and
e. Standardized outcome achievement criteria, applied consistently
across all diagnoses and severity of neonates (Carter et aI., 1999;
McLean et aI., 2002).
Through the use of expert neonatologists, a collaborative process is
created.

Nurse practitioners are able to collect, analyze and interpret case-

specific data while applying a systematic set of management principles to the
case.

In addition, the clinical consultants and nurse practitioners work in a

collaborative and collegial manner with the families and treating physicians of the
high risk infants for purposes of family (parental) education and discharge
planning (Cope, Bryant et aI., 2001; Gardner, 1999). See Appendix B.

SCM: A Model Solution

The SCM model is specifically designed to ensure that each provider
along the continuum of care has the necessary expertise to identify and address
the appropriate clinical problem(s) with the most efficient resource consumption
in order to provide the optimal clinical outcome. SCM involves the following eightstep process (Carter et aI., 1999; Gardner, 1999):

•

Step 1.

High-risk maternity screening and consultation.

The most cost-

effective care management of a high-risk neonate is prevention. A significant
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impact, clinically and financially, can be made on the trajectory of care for an
infant during the first few hours after birth, depending on the specifics of the
delivery. The objective of this phase of care is to help the high-risk mother
identify the most appropriate hospital for delivery (one capable of managing a
high-risk neonate).
•

Step 2. On-site assessment. At the time of the NICU admission, a
comprehensive on-site assessment is completed. The data from this
assessment are entered into a system to be used in prediction, outcome plan
development, and management of the critically ill newborn.

•

Step 3. Physician to physician communication. Using this initial data, the
ParadigmHealth neonatologist communicates with the attending neonatologist
to discuss the infant's trajectory of care, taking into consideration projected
lengths of stay at each level of care within the NICU, specific clinical problems
and risks that are anticipated in care management, and the overall plan of
care to achieve an efficient, effective, and safe discharge home.

•

Step 4. Case conceptualization. Equipped with the data from the
assessment, the care manager's observations, the neonatologist's
information, and clinical impressions gleaned from the attending physician,
the team conceptualizes the case, develops a budget to manage the case
and compares this case information to similar cases in the SCM database.

•

Step 5. Finalization of the outcome plan. After further data are obtained
regarding questions or issues generated during step 4, a final outcome plan
and budget to achieve that outcome are developed.
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•

Step 6. Clinical management focus. Once the outcome plan is in process,
the team meets on a regular basis to review key components of the case,
including the status of clinical problems and risks, the provider's relationship
and alignment, the family's understanding regarding the infant's projected
needs and their preparation to meet those needs, and the budget status.
From this, the team is able to identify the focus of clinical management for the
next reporting period.

•

Step 7. Discharge planning. While discharge planning begins the day of
NICU admission, s specific tool is used to enhance this process and ensure
that all the details are addressed to facilitate a timely discharge. In addition,
discharge criteria are reviewed at each clinical team meeting.

•

Step 8. Outcome achievement. The outcome achievement criteria are
reviewed at each clinical team meeting, and, once the criteria are met, a
.."

report is prepared to document the supporting evidence for achievement of
the outcome plan. This report is presented to the health plan (or employer)
client for their concurrence and audit, and then the case closure process
begins.

A unique feature of the SCM model is that the PMDs have no direct role in
patient treatment or coverage decisions and, hence, should not artificially restrict
resources for a given patient (Bryant, 2002). The focus is not to simply reduce
the patient's length of stay in the NICU, but to collaborate with the attending
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physician in orchestrating effective outcome management (Cope, Bryant et aI.,
2001). This is accomplished through
1. Collecting data directly from the attending physicians;

2. Providing clinical and scientific expertise to the clinical team; and
3. Analyzing data and clinical events.
The SCM team includes registered nurses or nurse practitioners with
extensive clinical and care management expertise, especially in the management
of neonatal complications or complex medical injuries/events (Bryant, 2002).
They are either under contractual arrangement with the company or are
employees, and provide either telephonic or on-site independent assessment
and management. In addition to providing actual case management, the team
nurses complete the data-collection tools that are the foundation for the SCM
database (Cope, Nathan et aI., 1995).
The SCM model is a collaborative system for managing very complex
patient care and recovery across the continuum of care, providing oversight,
access to data on outcomes of various treatment choices, and a broader level of
expertise in its program providers (Gardner, 1999). ParadigmHealth provides the
attending physician with external expertise, which can either supplement the
attending physician's skills and knowledge base or confirm the appropriateness
of the care being provided. The attending physician is empowered to establish
the appropriate allocation of resources and gains a greater understanding of total
costs compared to traditional systems. Through this feedback mechanism, the
SCM model provides a powerful foundation for understanding the consequences
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of care decisions for complex medicine. The SCM model contributes to the
health care process, following Eddy's suggestion,
The solution [to practice variability] is not to remove the decision-making
power from physicians, but to improve the capacity of physicians to make
better decisions. To achieve this solution, we must give physicians the
information they need; we must institutionalize the skills to use that
information; and we must build processes that support, not dictate,
decisions. (Eddy, 1996, p. 8)
Under the SCM model, the patient and their course of care are
continuously and comprehensively managed from the date of the initial onsite
through completion of the outcome plan and case closure, or until the case is
formally returned to the health plan for their internal management (Carter et aI.,
1999). This pattern of aggressive, timely on-site and telephonic care
management, consistently applied throughout the entire course of the outcome
plan, allows ParadigmHealth to intervene in the most appropriate fashion with
minimal delay, thereby promoting an optimal course of recovery for the patient.
To facilitate communication of the patient's progress, the SCM model includes a
battery of written reports, telephonic updates, and internal teleconferences that
provide consistent, timely and accurate information on the patient's status
(Bryant, 2002). These set the foundation for a system of communication and
accountability for the stakeholders (Cope, Bryant et aI., 2001).
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SCM tools. To facilitate objectivity, ParadigmHealth uses data tools that
permit objective comparisons of current case data with past performance, with
statewide and national data, and with expert clinical judgment (Gardner, 1999).
The internal data capture tool from which all other individual case specific data is
extracted contains over 500 variables and provides the CMT with the necessary
clinical, demographic, provider, and health plan information to begin
management of the case and development of an outcome or clinical
management.
Another major internal tool used in budget development is the "Complexity
Calculator." This Complexity tool is a risk-adjustment strategy that is data based
and consists of a statistically derived set of diagnosis specific variables and their
assigned multiple regression beta weights (Bryant, 2002). The diagnosis-specific
variables were initially selected through the use of a modified Delphi
methodology (Normand, McNeil, Peterson, & Palmer, 1998; Turoff & Hiltz, 1996)
using groups of physician experts from each diagnosis-related field. The
statistically derived variable set along with financial data were then entered into a
regression analysis in order to develop a set of weights for the variables that
would best predict resource consumption (length of stay and total costs) for each
diagnosis (for the Neonate Complexity Calculator, both internal data and data
from the California Office of Statewide Health Planning and Development were
used.) Multiple regression scores were then grouped (by the level of resources
consumed) in order to establish a resource utilization scale for the SCM model.
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To provide an estimate of external validation for the Complexity construct,
the same set of variables and data were given to a second set of physician
experts who were "blind" to the statistical Complexity projections. These
physician experts were then asked to make their own assessment of severity and
probable resource utilization and to assign their own complexity level of each
case. Subsequent correlation analysis revealed a 0.9 or greater correlation
between the Complexity Calculator estimates and those of the physician experts.
Such high correlations suggest that the Complexity Calculator does provide a
reliable estimate of severity and support the concept of the Complexity Calculator
as a reliable predictor of resource consumption (Bryant, 2002).
The third set of budget development tools is two statistical tables derived
from the ParadigmHealth internal database. These tables provide the DCS with
actual data from prior, similar ParadigmHealth cases to which the current case
can be compared.

Application of a modified De/phi methodology in SCM. SCM was
designed as a management model that is both database driven and "clinical
expert" driven. To ensure that the clinical expert component was statistically
grounded,

a modified Delphi Methodology was employed whenever clinically and

medically complex forecasting strategies needed to be developed. Helmer
(1983) of the Rand Corporation originally developed the Delphi Methodology, a
structured, multi-pass group decision process designed to address problems that
require professional expertise to achieve resolution, in the 1950's for
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technological and military forecasting (Linstone & Turoff, 1975). In the ensuing
40 years the approach has commonly been adopted in medicine, nursing,
psychology, and health care. The object of the Delphi method is to
systematically obtain reliable responses to complex problems from a group of
experts (Helmer, 1983; Normand et aI., 1998). As such, it recognizes human
judgments as legitimate and useful inputs for generating forecasts. The process
involves giving the panel of experts a series of questionnaires or interviews in an
iterative fashion while providing them with controlled opinion feedback about their
own and the other experts' responses after each data gathering session (Turoff &
Hiltz, 1996). The process has the following three core elements:
1. Structuring of information flow;
2. Feedback to the participants; and
3. Anonymity for the participants (that is, each participant's responses are
kept anonymous relative to the other members of the panel, thereby
preventing the "halo" effect.)
The SCM model has employed a modified Delphi Methodology primarily in
the areas of severity risk-adjustment (development of the Complexity Calculator)
and in estimating cost-savings through medical complication prevention (Cope,
Bryant et aI., 2001; Bryant, 2002). As mentioned previously in this paper, severity
risk-adjustment is a complex process at best; yet it is essential when comparing
patient populations, especially across cost and outcome parameters, which are
highly susceptible to even minor variations in medical severity. To address this
issue, ParadigmHealth used a panel of clinical experts in the fields of
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rehabilitation, physical medicine, orthopedics, trauma, burns, and neonatology
and employed a modified Delphi Method to develop a list of those variables for
each diagnosis which they expected to be most directly related to resource
utilization (McLean et al., 2002). The panel of experts was selected based upon
those variables, along with cost and length of stay data (and for neonates
appropriate data from the state and national databases as well). They were then
entered into a series of regression analyses, from which ranges for Complexity
Levels were established. Subsequent to completion of that initial research, a
Complexity Level has been calculated and recorded in the ParadigmHealth
database for all patients with risk-bearing contracts. Over time the database has
grown substantially in size. To further improve precision in resource utilization
prediction, this larger database has then been used to re-calculate the beta
weights for all of the variables (Bryant, 2002).
ParadigmHealth has also used

amodified Delphi Methodology in

developing two other (Bryant, 2002) savings estimates:
1. Selection of the primary risks related to a given diagnosis and in
setting differential levels of resource utilization depending upon the
severity of risk expression, and
2. Setting estimates of cost savings when neonates are placed in facilities
that support ParadigmHealth's SCM model versus being placed in
those facilities that choose to not participate.
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A panel of experts for each diagnosis was chosen with the project
coordinator serving as leader/facilitator. Panelists were from various medical
facilities across the country and participated telephonically and via e-mail.
Anonymity in the response summary was maintained. Over the course of 2-3
iterations members of each of the panels were able to come to mutual agreement
on their respective core issues (Bryant, 2002).
It should be stated that the Delphi Methodology has its limitations as a
research technique; specifically, (a) problem selection needs to be restricted to
those decisions that lend themselves to the use of group involvement; (b) the
process is iterative and as such can take significant time to complete, especially
if panel members have limited time to invest in the process; and (c) finding a
panel of experts can be challenging for some topics. Nonetheless, the Delphi
technique has reached a stage of maturity and continues to be actively used in
health care research due to the complexity of health care issues. It is
ParadigmHealth's contention that, since the savings estimates described above
were developed systematically using the Delphi methodology, in so far as
ParadigmHealth can demonstrate that through its actions a given risk either did
not become an active problem or its expression was milder than it would have
been without the firm's management, or that a length of stay at a specific level of
care was reduced through implementation of the SCM model, then
ParadigmHealth can accurately assert that the dollars associated with that risk
and severity level or length of stay are true cost savings (Cope, Bryant et aI.,
2001 ).
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The Evidence for SCM
The objective of systematic care management is to scientifically refine
care processes over time by iteratively examining relationships between process
and outcome, eliminating inappropriate services, and enhancing both the
efficiency and the outcome of the care that is delivered. There is evidence that
early iterations of this model of care have been effective; i.e., that when
timeliness and expertise were introduced into the care of catastrophically injured
patients, significant cost reductions resulted (Cope & Q'Lear, 1993; Gardner,
1999; McLean et aI., 2002).
The components of SCM include provider selection and education;
comprehensive assessment and treatment plans; an emphasis on patientspecific outcomes extending beyond the acute phase into community re-

integration; development, use and re-evaluation of clinical guidelines and
protocols; and data-driven evaluation of cost effectiveness and the relationships
between process and outcome (Cope & O'Lear, 1993; Cope, Bryant et aI., 2001).
In typical managed care systems, utilization review and other attempts to
address medial necessity have been hampered by a lack of evidence about the
differential effectiveness of alternative clinical pathways; establishing clinical
guidelines has been stymied by the lack of clearly defined outcome measures;
and most quality assurance requirements have focused on the processes of care
not on the outcomes of the care received. For catastrophic injuries where care
extends over a longer term, it is essential that the focus of quality include the
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outcomes of care and the relationship of outcomes to processes (Bryant, 2002;
Gardner, 1999).
The key to the effectiveness of the SCM model is the combination of
clinical evidence and data on patient characteristics and costs (Carter et al.,
1999). SCM is differentiated by its long-term, comprehensive, providercollaborative, data-driven approach to care. It utilizes the available evidence
about alternative clinical practices and their costs as well as their immediate and
long-term outcomes and costs. It takes into account the full continuum of
necessary services over the patient's entire episode of care (and often remaining
life span) in assessing the relative utility of alternative therapies.
A feasibility assessment of the SCM model confirmed the health care
industry's readiness to adopt such a system (Cope & O'Lear, 1993; Jencks,
1997). Another assessment of the potential of a SCM model found that
purchasers, providers, payers, consumers and policymakers alike support a
system that is based on results not just processes of care (Jencks, 1997).

III. Methodology
This study will quantitatively compare neonatal average lengths of hospital
stays (ALaS) and length of stay range between the ParadigmHealth dataset and
the MillimanUSA dataset (MillimanUSA, 2002). The study will duplicate the same
comparison between the ParadigmHealth dataset and the dataset from
California's Office of Statewide Planning and Development (OSHPD, 2002).
The OSHPD dataset is a subset of the MillimanUSA dataset. This
secondary comparison is being done due to the linking of transfer cases that are
unique to the California dataset. Researchers at Stanford University
methodically matched transfer cases so that infants transferred from one NICU
setting to another were counted as one complete case rather than two separate
patients (Phibbs, Bronstein et aI., 1996). The results of this linking process have
been used to adjust the larger MillimanUSA dataset to account for these transfer
cases. The aim of the study is to determine whether ParadigmHealth's
Systematic Care Management (SCM) process reduces average length of stay
(ALOS) in the NICU population. In addition, the researcher would like to
determine whether the SCM process also reduces the range in the total LOS for
the high-risk neonate population.
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Data Classification and Framework

The study will use data derived by ParadigmHealth's management of
NICU cases for a three-year period (1998 - 2000), data obtained from
MillimanUSA for the same period sourced from the Health care Cost and
Utilization Project (HCUP), and data obtained as a subset of the MillimanUSA
dataset from the California's Office of Statewide Planning and Development
(OSHPD) for the same period. These datasets have been compiled using the
patient classification system that was developed by 3M Health Information
Systems (3M, 1995) referred to as the APR-DRGs (All Patient Refined Diagnosis
Related Groups). This classification system is modeled after the All Patients
Diagnosis Related Group (AP-DRG) system. This classification system uses
hospital patient discharge data and computer-based logic to assign patients to
severity of illness and risk of mortality classes so that they can be accurately
compared in terms of length of stay, resource consumption and outcomes (Averill
et aI., 1997). This APR-DRG system was developed as a joint venture between the
New York Department of Health and 3M Health Information Systems as a result of
1987 state legislation that stipulated the development of a DRG-based prospective
payment system for the payment of all non-Medicare patients. The All-Patient DRG
system (AP-DRG) was developed for this purpose and then refined in 1990 (APRDRG) as a better measure for not only resource intensity, but also matching
resource intensity with severity of illness and risk of mortality. Three subsequent
updates to the classification categories have been released since 1990 with the
latest being completed in 1998 (3M, 1995). In refining the system to include severity
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and mortality adjustment factors, it is now possible to use these patient
classifications for endeavors such as the following:
•

Comparing hospitals across a wide range of resource and outcome
measures,

•

Evaluating differences in inpatient mortality rates,

•

Assessing possible causes for variation to develop evidence-based
best practices,

•

Implementing and monitoring the success of clinical pathways,

•

Providing individual or group profiles and opportunities for objective
feedback,

•

Identifying areas for continuous quality improvement initiatives,

•

Identification of patients benefiting from case management, and

•

Improving the quality of care (Averill et aI., 1997).

There are 6 total All-Patient DRG's that deal with non-normal newborns.
The APR-DRG's add a much greater level of granularity by expanding the
number of classes from these 6 neonate AP-DRG's to 35 neonate APR-DRG's.
Further, the APR-DRG system adds four subclasses to this framework,
incorporating severity of illness and risk of mortality to address patient
differences and allow for superior severity adjustment within APR-DRG
classifications (See Table 1). The four subclasses are numbered sequentially
from 1 to 4 and indicate minor, moderate, major or extreme severity of illness or
risk of mortality. Thus, via the APR-DRG system's decision-tree methodology,
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each patient is assigned three distinct descriptors: base APR-DRG, severity of
illness subclass, and risk of mortality subclass (e.g. 590-4-3 would be a baby
with a birthweight of less than 750 grams with major procedures, a severity of
illness within that classification of 4 and a risk of mortality of 3).
APR-DRG Version 15.0, the most recent version of the software (3M,
1995), utilizes 357 diagnostic related groups (DRG's), each with four severity of
illness subclasses and four risk of mortality subclasses for a total of 1422 APRDRG's. This is the most comprehensive and widely used patient classification
system in existence.
A major investigation was conducted in which 4,203,646 hospital
discharge records of patients were analyzed and a comparison was made of the
DRG system versus the APR-DRG system for predictive accuracy of patient
costs (Averil et aI., 1997). The predictive accuracy of the APR-DRG system was
30.3% higher than that of the DRG sysfem.
For neonatal services, there are 33 primary diagnostic categories with four
severity levels for each of these categories, resulting in 132 APR-DRG severity
classifications or groupers. The four severity levels are based upon the number
of secondary ICD-9 diagnostic and procedures codes as well as the interaction
between these ICD-9 codes. This process is captured algorithmically in the 3M
model. The determination of the specific APR-DRG category that is assigned to
a patient is made based on the hospital discharge billing form (known as the U892 form) submitted by the treating hospital. The base APR-DRG, severity of

49

illness and risk of mortality subclass determination is a three-phase process,
wholly contained within the 3M model protocols.
For the ParadigmHealth dataset, inputs the demographic information and
all known ICD-9 diagnosis and procedure codes were done to allow the grouper
software to accurately and finely determine the APR-DRG and subclasses. As
mentioned, the first phase begins as the grouper software assigns the base APRDRG. The severity of illness and risk of mortality subclass determination is
completed during the second and third phase respectively, in which the
classification system takes into consideration factors such as age, principal
diagnosis, operating and non-operating procedures present, interaction among
and combinations of categories of secondary diagnoses in making the final
determination (McLean et aI., 2002).
The final determination of APR-DRG classification for each neonatal
referral is based on discharge information readily available on the UB-92, such
as primary and secondary diagnoses, and principal and secondary procedure
codes. Paradigm utilizes the 3M Grouper Software to objectively assess APRDRG classification at the time of referral to get a picture of severity, risk of
mortality and potential resource utilization; however, additional procedures and
secondary diagnoses only available at discharge, will ultimately affect the final
determination of the APR-DRG base group and severity of illness and risk of
mortality classifications (Bryant, 2002).
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Aims of the Study
This study had two primary goals:
1. To determine whether the SCM process of management is associated
with significant reductions in the average length of stay (ALOS) of
complex, high-risk neonates during their initial NICU hospitalization.
2. To determine whether SCM is effective in reducing the range in NICU
lengths of stay within APR-DRG groups.

Primary Research Question
ParadigmHealth's Systematic Care Management (SCM) is a process
specifically designed to address the challenge of extremely complex medical
problems (Bryant, 2002; Gardner, 1999). This care process is different from
existing methods of management in that it is data driven, provider collaborative,
and outcome focused (Bryant, 2002; Gardner, 1999; McLean et aI., 2002). This
analysis will address the question "is there quantitative support that such
management results in a reduction in ALOS as well as a reduction in the range of
patient length of stay in the high-risk neonate population?"

Research Hypotheses
The study had two primary hypotheses:
H1:

There is evidence that ParadigmHealth's Systematic Care
Management (SCM) process results in a reduction in NICU average
length of stay (ALOS).
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H2:

There is evidence that the SCM process reduces the range of
patient length of stay) in the high-risk neonate (NICU) population.

Null Hypotheses
Following the two hypotheses presented above, there were two null
hypotheses under study:
Ho1:

There is no evidence that ParadigmHealth's Systematic Care
Management (SCM) process results in a reduction in NICU average
length of stay (ALOS).

Ho2:

There is no evidence that the SCM process reduces the range of
patient length of stay) in the high-risk neonate (NICU) population.

Study Design and Analysis
A t-test is utilized to test for statistically significant differences in the
means between the ParadigmHealth dataset and the two comparison datasets.
The individual APR-DRG means of the Paradigm dataset will be compared to the
means for the MillimanUSA dataset and the OSHPD dataset Using SAS (1986)
tools, the analysis will produce two t-test, the relevant one depending on whether
the differences are equal or unequal. A folded F-test is utilized to test the equality
of variance. This equality of variance test illuminates the reasonableness of the
assumption of equal variances versus unequal variances for these datasets,
given a normal distribution. The folded F-test is a test of the results of a
statistical analysis, perhaps most closely associated with, but by no means
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limited to, analysis of variance. If the F-test has a significant p-value (P < .05),
then the t-test for unequal variances will be used to evaluate the APR-DRG. If
the F-test produces a p-value greater than .05, the t-test for equal variances will
be used to evaluate the APR-DRG.
If the equality of variances illustrates the reasonableness of equal
variances, then the appropriate statistical test for this analysis is the pooled t-test,
which tests the assumption of equal variances. If the equality of variances
illustrates the unreasonableness of equal variances, then the appropriate
statistical test for this analysis is the Satterthwaite test (Satterthwaite, 1946),
which tests for the hypothesis of unequal variances.
Acknowledging that probability is a continuum, if p-value >= .05, then it is
likely that the differences are not statistically significant to support unequal
variance in t-test. If, however, the p-value < .05, then it is likely that the
differences are unequal between the sa~mples. Since the statistical significance
is a continuum (.05 is an arbitrary cut point) and the ParadigmHealth database
contains certain APR-DRG cells that have relatively small sample sizes, it is
possible that a p-value between .05 and .1 could be significant if the difference
between the two means is relatively large.

Paradigm Sample
The Paradigm sample of cases is comprised of over 500 infants referred
to ParadigmHealth from 1998 through 2000. These neonates represent a broad
spectrum of clinical severity, comprising 82 distinct APR-DRG I Severity
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combinations from 40 states. (There are 132 total possible distinct APR-DRG I
Severity combinations.) While the top five referring states represent 850/0 of the
ParadigmHealth dataset, they are geographically dispersed, including California,
New Mexico, Texas, Wisconsin, and Pennsylvania. The sample is balanced
between males and females with males representing 52% of the dataset.
In some instances, a ParadigmHealth case may be included in one or both
of the other two datasets. ParadigmHealth's California cases will be included in
the OSHPD dataset and the MillimanUSA dataset. In addition, non-California
ParadigmHealth cases originating from one of the states that participate in the
Healthcare Cost and Utilization Project (HCUP) database from the Agency for
Healthcare Research and Quality will be counted in the MillimanUSA dataset as
well as this is the primary source for the MillimanUSA dataset.

Comparison Sample
The primary comparison sample to be used is the MillimanUSA dataset.
The most extensive national neonatal database currently available, the
MillimanUSA dataset's principal underlying data source is the Healthcare Cost
and Utilization Project (HCUP) database from the Agency for Healthcare
Research and Quality. This nationwide inpatient sample (NIS) contains data from
approximately 7 million hospital stays.
The NIS contains all discharge data from approximately 1,000 hospitals
located in 22 States, approximating a 20-percent stratified sample of U.S.
community hospitals. There are a total of 3,707,351 births in this sample and
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318,249 NICU cases. For this study, a sub-sample of the NICU total cases will
be used, which will be matched to the ParadigmHealth sample by APR DRG
classification (for the 82 distinct severity combinations within the ParadigmHealth
dataset). This sample will include approximately 130,000 NICU cases from the
MillimanUSA dataset. The information included in the dataset ranges from
discrete physiological measures to ICD-9 diagnosis and procedure codes, as well
as detailed billed and paid NICU cost data.
A secondary comparison sample will be data from the California data from
the Office of Statewide Planning and Development (OSHPD). This database
enhances the MillimanUSA dataset by providing more clinical information and
allowing for tracking of neonates who transferred from one acute facility to
another in order to fully estimate the length of stay associated with a given birth
episode. This second comparison sample is utilized as a separate control group
against which to compare ParadigmHealth's dataset. . This sample will include
approximately 22,000 NICU cases from the OSHPD dataset.

Delimitations
This study effort may be limited by the nature of the research datasets used
in this analysis. In order to control for facility coding and billing practices of
providers within its database, the MillimanUSA dataset excludes neonatal deaths
and infants discharged from the NICU within 5 days of admission, as such short
stays are not representative of the general neonatal intensive care population.
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In addition, while nationally recognized as the best severity adjustment
parameter currently available in neonatal care, the APR-DRG weighted score for
a patient may be influenced by human error in the classification and recording of
secondary diagnosis and procedure codes. Each APR-DRG and its
corresponding severity modifiers are derived by the combination of diagnostic
and procedure codes created on the hospital billing form (UB-92).
This research assumes the presence of nationally accepted evidence-based
protocols for the care of high-risk infants in neonatal intensive care. The real
world variability in neonatal intensive care practices (and their resultant
outcomes) across facilities, regions and the nation present a limitation and
challenge to this research effort.
Finally, use of the MillimanUSA dataset and the California OSHPD dataset
as a convenience sample for this study, while robust, may not represent the
actual practice patterns of the nation's NICUs . As such, conclusions drawn for
this study may have limited applicability or clinical relevance to nation-wide
neonatal intensive care practice.
While both datasets include infant transfers among NICUs, the transfer
cases within the MillimanUSA set are linked using the results of the California
data from the Office of Statewide Planning and Development (OSHPD). This
OSHPD dataset enhances the MillimanUSA dataset by providing a methodology
to assume the proportion of neonates within the MillimanUSA dataset who
transferred from one acute facility to another. The transfer rates from the
OSHPD dataset are used to accurately estimate the acute length of stay
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associated with a given birth episode for neonatal cases in the MillimanUSA
dataset.

Birlhweight Categories and Sample Sizes
A listing of the Neonatal APR-DRG codes and descriptions is provided in
Table 1. These APR-DRGs are grouped into the following birthweight
categories:
•

ECMO Procedures

•

Infants with Birthweight < 750 Grams

•

Infants with Birthweight 750 - 999 Grams

•

Infants with Birthweight 1000 - 1499 Grams

•

Infants with Birthweight 1500 - 1999 Grams

•

Infants with Birthweight 2000 - 2499 Grams, and

•

Infants with Birthweight > 2499 Grams
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Table 1
APR-DRG Classification Description
Severity Scale
APR-DRG

Description of Neonate APR-DRG

580

Neonate, Transferred < 5 days old, not born here

581

Neonate, Transferred < 5 days old, born here

582

With organ Transplant

583

With ECMO

590

Birthweight < 750G w major procedure

591

Birthweight < 750G w/o major procedure

592

Birthweight 750G-999G w major procedure

593

Birthweight 750G-999Gw/o major procedure

600

Birthweight 1000-1499G w major procedure

601

Birthweight 1000-1499G w major anomaly or hereditary condition

602

Birthweight 1000.. 1499G w respiratory distress syndrome

603

Other Birthweight 1000-1499G

610

Birthweight 1500-1999G w major procedure

611

Birthweight I 500-1999G w major anomaly or hereditary condition

612

Birthweight 1500-1999G w respiratory distress syndrome

613

Birthweight 1500-1999G w congenital or perinatal infection

614

Other Birthweight 1500-1999G

620

Birthweight 2000 ...2499G w major pr5>cedure

621

Birthweight 2000-2499G w major anomaly or hereditary condition

622

Birthweight 2000-2499G w respiratory distress syndrome

623

Birthweight 2000-2499G w congenital or perinatal infection

624

Birthweight 2000-2499G not born here

625

Birthweight 2000-2499G born here, w other significant condition

626

Birthweight 2000-2499G, born here, normal nb & nb w other probs

630

Birthweight >2499G, w major cardiovascular procedure

631

Birthweight >2499G

632

Birthweight >2499G w other procedure

633

Birthweight >2499G w major anomaly or hereditary condition

634

Birthweight >2499G w respiratory distress syndrome

635

Birthweight >2499G W aspiration syndrome

636

Birthweight >2499G W congenital or perinatal infection

637

Birthweight >2499G not born here, w other significant conditions

638

Birthweight >2499G, not born here, w other problems

639

Birthweight >2499G, born here, w other significant conditions

640

Birthweight >2499G, born here, normal nb & nb w other probs

w other major procedure

1

234
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A listing of those APR-DRGs included in the study for ECMO procedures
is shown in Table 2. This special category is established for those infants with
such significant respiratory distress that an ECMO procedure (surgical
intervention to stimulate lung development) is performed.

Table 2
Sample Size for Birthweight Group with ECMO

Birthweight: ECMO Procedures
APRParadigm
OSHPD
DRG
583/2
2
8
583/4
4
0

Total n for Birthweight Class
Milliman

Paradigm

OSHPD

Milliman

74
40

6

8

114

A listing of those APR-DRGs included in the study for the second
birthweight category, those with birth weights < 750 grams, is shown in Table 3.
There are 32 ParadigmHealth cases, 255 OSHPD cases, and 3,478
MillimanUSA cases in this birthweight category.
Table 3
Sample Size for Birthweight Group < 750 Grams

Birthweight: < 750 Grams
APRParadigm
OSHPD
DRG
590/3
1
3
590/4
7
58
591/3
1
19
591/4
23
175

Total n for Birthweight Class
Milliman

Paradigm

OSHPD

Milliman

40
669
271
2498

32

255

3478
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A listing of those APR-DRGs included in the study for the third birthweight
category, those with birth weights ranging from 750 to 999 grams, is shown in
Table 4. There are 58 ParadigmHealth cases, 493 OSHPD cases, and 6,148
MillimanUSA cases in this birthweight category.

Table 4
Sample Size for Birthweight Group 750 - 999 Grams

Birthweight: 750 - 999 Grams
APRParadigm
OSHPD
DRG
592/4
13
47
593/2
1
27
593/3
12
77
593/4
32
342

Total n for Birthweight Class
Milliman

Paradigm

OSHPD

Milliman

550
442
1219
3937

58

493

6148

A listing of those APR-DRGs included in the study for the fourth
birthweight category, those with birth w~ights ranging from 1,000 to 1,499 grams,
is shown in Table 5. There are 145 ParadigmHealth cases, 1,627 OSHPD
cases, and 18,067 MillimanUSA cases in this birthweight category.
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Table 5
Sample Size for Birthweight Group 1000 - 1499 Grams

Birthweight: 1000 - 1499 Grams
APRParadigm
OSHPD
DRG
600/3
1
1
600/4
5
54
601/1
1
6
601/3
6
70
601/4
4
106
602/1
1
21
602/2
10
70
602/3
33
268
602/4
37
302
603/1
6
127
603/2
9
288
603/3
18
204
603/4
14
110

Total n for Birthweight Class
Milliman

Paradigm

OSHPD

Milliman

95
457
78
906
853
276
1264
3350
2962
1065
3404
2483
874

145

1627

18067

A listing of those APR-DRGs included in the study for the fifth birthweight
category, those with birth weights ranging from 1,500 to 1,999 grams, is shown in
Table 6. There are 147 ParadigmHealth cases, 3,604 OSHPD cases, and
37,616 MillimanUSA cases in this birthweight category.
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Table 6
Sample Size for Birthweight Group 1500 - 1999 Grams

Birthweight: 1500 - 1999 Grams
APRParadigm
OSHPD
DRG
610/2
1
2
610/3
14
1
29
610/4
4
38
611/1
1
611/2
1
79
611/3
93
3
10
611/4
52
612/1
2
109
204
612/2
12
612/3
285
24
132
612/4
12
613/2
127
2
162
613/3
1
613/4
4
33
614/1
27
1055
614/2
17
946
614/3
210
18
614/4
34
7

Total n for Birthweight Class
Milliman

Paradigm

OSHPD

Milliman

47
134
297
395
1075
1007
401
1133
2345
3106
1208
1510
1774
268
10842
£}740
2083
251

147

3604

37616

A listing of those APR-DRGs included in the study for the sixth birthweight
category, those with birth weights ranging from 2,000 to 2,499 grams, is shown in
Table 7. There are 55 ParadigmHealth cases, 4,294 OSHPD cases, and 29,086
MillimanUSA cases in this birthweight category.
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Table 7
Sample Size for Birthweight Group 2000 - 2499 Grams

Birthweight: 2000 - 2499 Grams
APR..
Paradigm
OSHPD
DRG
620/4
3
34
621/1
1
47
621/2
96
1
621/3
5
77
621/4
33
4
622/1
2
158
622/2
5
216
622/3
3
196
622/4
4
85
623/1
138
2
623/2
1
147
623/3
3
201
625/1
3
876
625/2
1
354
625/3
141
7
626/2
4
635
626/3
6
860

Total n for Birthweight Class
Milliman

Paradigm

OSHPD

Milliman

310
507
973
724
227
1527
2320
2144
670
1524
1630
1858
7549
2790
1105
J 191
2037

55

4294

29086

A listing of those APR-DRGs included in the study for the seventh
birthweight category, those with birth weights> 2499 grams, is shown in Table 8.
There are 89 ParadigmHealth cases, 11 ,922 OSHPD cases, and 42,622
MillimanUSA cases in this birthweight category.
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Table 8
Sample Size for Birthweight Group> 2499 Grams

Birthweight: > 2499 Grams
APROSHPD
Paradigm
DRG
630/4
49
10
631/2
59
4
631/3
67
6
631/4
11
84
23
632/2
1
632/3
28
1
632/4
14
1
633/1
162
1
633/3
273
4
633/4
8
113
634/2
2
638
634/3
477
2
634/4
5
197
635/3
264
2
635/4
72
2
636/2
737
1
636/4
88
3
639/1
4
1117
639/2
3
1221
639/3
436
8
639/4
40
3
640/1
2306
2
640/2
2000
2
640/3
1457
3

Total n for Birthweight Class
Milliman

Paradigm

OSHPD

Milliman

89

11922

42622

600
829
1074
1357
280
394
279
1581
3116
1370
5369
4910
2104
1995
552
~7892

987
1681
2115
989
201
720
1137
1090

IV. Results

While the datasets all represent neonatal admissions, the distribution of the
cases across the various APR-DRGs (as well as across the corresponding
weight groups) varies, as shown in Table 9. The ParadigmHealth dataset
contains a total of 532 cases, the OSHPD dataset 22,203 cases, and the
MillimanUSA dataset 127,131 cases.
Table 9
Distribution of Cases by Birlhweight

Paradigm
Health

OSHPD
(CA)

Milliman
USA

6

8

114

< 750 G

32

255

3,478

750 - 999G

58

493

6,148

1000 - 1499G

145

1,627

18,067

1500 - 1999G

147

3,604

37,616

2000 - 2499G

55

4,294

29,086

>2499G

89

11,922

42,622

532

22,203

137,131

Sam~le

Size

ECMO

Total Sample Size

The ParadigmHealth dataset contained a greater proportion of cases in
the smaller birthweight groups (Table 10). For the ParadigmHealth dataset, the
ECMO category (those infants with severe respiratory distress) represented
1.130/0 of the dataset while only 0.04% for the OSHPD dataset and 0.080/0 for the
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MillimanUSA dataset. Infants weighing less than 1000 grams, and the most
medically fragile group of neonates, represented 16.920/0 of the ParadigmHealth
dataset, 3.37% of the OSHPD dataset, and 7.120/0 of the MillimanUSA dataset.
Infants weighing at least 1000 grams but less than 2000 grams represented
54.89% of the ParadigmHealth dataset, 23.560/0 of the OSHPD dataset, and
40.50/0 of the MillimanUSA dataset. Infants with birthweight of greater than 1999
grams comprised 27.07% of the ParadigmHealth dataset, 73.040/0 of the OSHPD
dataset, and 52.29% of the MillimanUSA dataset.

Table 10
Percentage Distribution of Cases by Birthweight

SamQle % Distribution
ECMO
< 750G
750 - 999G
1000 - 1499G
1500 - 1999G
2000 - 2499G
>2499G
Total Sample Size

Paradigm
OSHPD
Milliman
USA
Health
{CAl
0.04%
1.13%
0.080/0
2.54%
6.02%
1.15%
2.22%
10.90 %
4.480/0
7.33%
27.26%
13.17%
27.630/0
16.230/0
27.43%
19.34%
10.34%
21.21%
53.700/0
31.080/0
16.730/0
100.00%
100.00 %
100.00%

The proportion of infants within each of the datasets that would be
considered very low birthweight (meaning < 1500 grams and ECMO categories)
was largest within the ParadigmHealth dataset comprising 45.31 % of the sample
while representing only 10.74% of the OSHPD dataset and 20.270/0 of the
MillimanUSA dataset respectively. This higher proportion of very low birthweight
infants in the ParadigmHealth dataset is expected given the sample is derived
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from the firm's business model of managing fragile and catastrophic neonates.
The relative proportion of infants across the various birthweight categories for the
three datasets is shown in Figure 1.

Sample Distribution by Birthweight
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0.04%

1.15%

2.22%

7.33%

16.23%

19.34%
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o MillimanUSA

0.08%

2.54%

4.48%

13.17%

27.43%

21.21%

31.08%

EJ

Paradigm Health

1000 - 1499G 1500 -1999G 2000 - 2499G

>2499G

Birthweight Category

Figure 1: Sample Distribution by Birlhweight: ParadigmHealth, OSHPD, and
MillimanUSA Datasets
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The first analysis completed for each APR-DRG was the F-test to determine
if the variances between the two data sets for that APR-DRG are equal. If the Ftest has a significant p-value (p < .05), then the Satterthwaite test (for unequal
variances) was used to determine if the variance between the two means of the
APR-DRG group was significant. If the F-test results in a p-value > .05, then the
pooled t-test (for equal valiances) was used to determine if the variance between
the two means of the APR-DRG group was significant.
Using the t-test methodology, if the p-value is > or = to .05, then it is likely
that the variances are not statistically significant to support a conclusion of
unequal variance in t-test.

If, however the p-value is < .05, then it is likely that

the variances are unequal between the samples and the differences in mean
values are significant. The t-test procedure was completed, comparing the mean
of ParadigmHealth dataset to the mean of the MillimanUSA dataset and the
mean of the OSHPD dataset. This tesfwas first done as an overall comparison
of the ALOS (matched using the DRG patient classification system) then by
birthweight Tiers (1000 gram increments), and finally by individual APR-DRG.

Overall Comparison: ParadigmHealth to MillimanUSA
The initial t-test procedure compared the means of the ParadigmHealth
dataset and the MillimanUSA dataset grouped by DRG. The results of the t-test
revealed that the ALOS of the ParadigmHealth dataset was 5.59 days, on
average, lower than the MillimanUSA ALOS for DRG-matched neonates (t =
4.28, P < 0.0001). The mean differences between the ALOS reductions of the
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ParadigmHealth and MillimanUSA samples ranged from 0 to 26 days (See
Figure 2). The greatest differences were in the extremely low birthweight group

« 1000 grams).

Difference in ALOS: ParadigmHealth & MillimanUSA
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Figure 2: Paradigm ALOS Difference from MillimanUSA by Birthweight

Comparison of Datasets by Birthweight Groups (Tiers)

The researcher then grouped the APR-DRGs into groupings or Tiers (See
Appendix C for definition and specific APR-DRG assignments to Tiers). Tier 1 is
comprised of those infants with birth weights of 2000 grams and greater (APRDRGs 620 -640, severity levels 1,2, and 3). Tier 2 is comprised of those infants
with birth weights that range from 1000 grams to 1999 grams (APR-DRGs 610614, severity levels 1,2, and 3; and APR-DRGs 600-603, severity levels 1 and 2).
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Tier 3 is comprised of those infants weighing < 1000 grams (APR-DRGs 590593, severity levels 1,2,3, and 4). Tier 4 is comprised of the highest severity
levels across all the various birthweight categories. It contains severity level four
(4) cases for APR-DRGs 610-640; APR-DRGs 600-603, severity levels 3 and 4;
and the entire ECMO and Organ Transplantation APR-DRG categories.
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ParadigmHealth to MillimanUSA analysis - tier 1. For Tier 1, the mean
ALOS of the ParadigmHealth dataset was 12.676 days, 3.6127 days less than
the mean ALOS for the MillimanUSA dataset (16.288 days). The F-test resulted
in a p-value of < 0.0001 and the resulting Satterthwaite t-test for unequal
variances yielded a p-value of 0.2990, thus the difference in the two means is not
statistically significant (See Table 11).

Table 11
Tier 1: ParadigmHealth to MillimanUSA: ALOS Comparison
Statistics

t-test procedure

N

Mean

15.75
5.8248
-13.72

16.288
12.676
3.6127

16.827
19.527
20.95

Minimum

Maximum

Variable

Dataset

ALOS
ALOS
ALOS

Milliman
Paradigm
Diff (1-2)

Variable

Dataset

Std Err

ALOS
ALOS
ALOS

Milliman
Paradigm
Diff (1-2)

0.2749
3.4479
8.8455

93194
90

Upper CL Lower CL
Mean Std Dev

LowerCL
Mean

83.496

T-Tests
Variable

Method

Variances

ALOS
AlOS

Pooled
Satterthwaite

Equal
Unequal

OF

t Value

Pr > I t I

93E3
90.1

0.41

1.04

0.683
0.299

Equality of Variances
Variable

Method

ALOS

Folded F

Num OF

Den OF

F Value

Pr> F

93193

89

6.58

< .0001

Std Dev
83.909
32.71
83.875

UpperCL
Std Dev

84.257
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ParadigmHealth to MillimanUSA analysis - tier 2. For Tier 2, the mean
ALOS of the ParadigmHealth dataset was 24.103 days, 3.25 days less than the
mean ALOS for the MillimanUSA dataset (27.361 days). The F-test resulted in a
p-value of < 0.0001 and the resulting Satterthwaite t-test for unequal variances
yielded a p-value of 0.2037, thus the difference in the two means is not
statistically significant (See Table 12).

Table 12
Tier 2: ParadigmHealth to MillimanUSA: ALOS Comparison
Statistics

t-test procedure

N

Mean

26.729
19.098
-7.921

27.361
24.103
3.258

27.994
29.108
14.437

Minimum

Maximum

Variable

Dataset

ALOS
ALOS
ALOS

Milliman
Paradigm
Diff (1-2)

Variable

Dataset

Std Err

ALOS
ALOS
ALOS

Milliman
Paradigm
Diff (1-2)

0.3228
2.531
5.7035

42732
137

Upper CL Lower CL
Mean Std Dev

Lower CL
Mean

Std Dev

66.208

T-Tests
Variable

Method

Variances

ALOS
ALOS

Pooled
Satterthwaite

Equal
Unequal

Pr > I t

I

DF

t Value

43E3
140

0.57
1.28

0.5678
0.2037

Equality of Variances
Variable

Method

ALOS

Folded F

Num DF

Den DF

F Value

Pr > F

42731

136

5.07

< .0001

66.736
29.624
66.651

Upper CL
Std Dev

67.1
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ParadigmHealth to MillimanUSA analysis - tier 3. For Tier 3, the mean
ALOS of the ParadigmHealth dataset was 88.102 days, 7.64 days less than the
mean ALOS for the MillimanUSA dataset (95.742 days). The F-test resulted in a
p-value of < 0.0001 and the resulting Satterthwaite t-test for unequal variances

yielded a p-value of 0.2213, thus the difference in the two means is not
statistically significant (See Table 13).

Table 13
Tier 3: ParadigmHealth to MillimanUSA: ALOS Comparison
Statistics

t..test procedure
Lower CL
Mean

Mean

92.919
76.105
-21.8

95.742
88.102
7.64

98.565
100.1
37.084

Minimum

Maximum

Variable

Dataset

N

ALOS
ALOS
ALOS

Miltiman
Paradigm
Diff (1-2)

9777
90

Variable

Dataset

Std Err

ALOS
ALOS
ALOS

Milliman
Paradigm
Oiff (1-2)

6.0379
15.021

Upper CL Lower CL
Mean Std Dev

139.9

1.44

T-Tests
Variable

Method

Variances

ALOS
ALOS

Pooled
Satterthwaite

Equal
Unequal

OF

t Value

Pr > I t I

9865
99.4

0.51
1.23

0.611
0.2213

Equality of Variances

Variable

Method

ALOS

Folded F

Num DF

Den DF

F Value

Pr > F

9776

89

6.18

< .0001

Std Dev
142.39
57.281
141.85

UpperCL
Std Dev

143.86

73

ParadigmHealth to MillimanUSA analysis - tier 4. For Tier 4, the mean
ALOS of the ParadigmHealth dataset was 41.781 days, 0.1969 days less than
the mean ALOS for the MillimanUSA dataset (41.978 days). The F-test resulted
in a p-value of < 0.0001 and the resulting Satterthwaite t-test for unequal
variances yielded a p-value of 0.9749, thus the difference in the two means is not
statistically significant (See Table 14).

Table 14
Tier 4: ParadigmHealth to MillimanUSA: ALOS Comparison
Statistics

t-test procedure
LowerCL
Mean

Mean

39.704
29.665
-23.83

41.978
41.781
0.1969

44.252
53.897
24.22

Dataset

Std Err

Minimum

Maximum

Milliman
Paradigm
Diff (1-2)

1.1601
6.1469
12.256

Variable

Dataset

ALaS
ALaS
ALOS

Milliman
Paradigm
Oiff (1-2)

Variable
ALas
ALas
ALOS

N
23943
215

Upper CL Lower CL
Mean Std Dev

Std Dev

177.33

T-Tests
Variable

Method

Variances

ALas
ALaS

Pooled
Satterthwaite

Equal
Unequal

Pr > I t

I

DF

t Value

24E3
230

0.02
0.03

0.9872
0.9749

Equality of Variances
Variable

Method

ALOS

Folded F

Num OF

Den DF

F Value

Pr> F

23942

214

3.97

< .0001

179.51
90.131
178.91

Upper CL
Std Dev

180.52
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Summary of findings for tiered comparisons. In each of the four Tiers, the

ParadigmHealth ALaS was found to be lower than the MillimanUSA ALOS. For
Tier 1, the ParadigmHealth ALaS was lower by 3.6 days (ParadigmHealth n

=

90). For Tier 2, the ParadigmHealth ALOS was lower by 3.3 days
(ParadigmHealth n = 137). For Tier 3, the ParadigmHealth ALOS was lower by
7.6 days, the largest difference of means within this Tier comparison
(ParadigmHealth n

=90).

For Tier 4, the ParadigmHealth ALaS was lower by

0.2 days (ParadigmHealth n

=215).

Yet, based upon the F-test and t-test

findings, none of these differences in the two means could be shown to be
statistically significant (p-values for the Satterthwaite t-test ranged from 0.2037 0.9749)
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ParadigmHealth to OSHPD analysis - tier 1" For Tier 1, the mean ALOS
of the ParadigmHealth dataset was 12.676 days, 0.0831 days less than the
mean ALOS for the OSHPD dataset (12.759 days). The F-test resulted in a pvalue of < 0.0001 and the resulting Satterthwaite t-test for unequal variances
yielded a p-value of 0.9445, thus the difference in the two means is not
statistically significant (See Table 15).

Table 15
Tier 1: ParadigmHealth to OSHPD: ALOS Comparison
Statistics

t-test procedure

N

Mean

12.457
10.329
-4.307

12.759
12.676
0.0831

13.061
15.022
4.473

Minimum

Maximum

DF

t Value

Pr > I t I

19E3
92.1

0.04
0.07

0.9704
0.9445

Variable

Dataset

ALOS
ALOS
ALOS

OSHPD
Paradigm
Diff (1-2)

Variable

Dataset

Std Err

ALOS
ALOS
ALOS

OSHPD
Paradigm
Diff (1-2)

0.154
1.1809
2.2397

Variable

Method

Variances

ALOS
ALOS

Pooled
Satterthwaite

Equal
Unequal

19002
90

Upper CL Lower CL
Mean Std Dev

LowerCL
Mean

20.987

Equality of Variances
Variable

Method

ALOS

Folded F

Num DF

Den DF

F Value

Pr > F

19001

89

3.59

< .0001

UpperCL
Std Dev
Std Dev
21.233
11.203
21.197

21.412
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ParadigmHealth to OSHPD analysis - tier 2. For Tier 2, the mean ALOS of
the ParadigmHealth dataset was 24.103 days, 1.5804 days less than the mean
ALOS for the OSHPD dataset (25.684 days). The F-test resulted in a p-value of
< 0.0001 and the resulting Satterthwaite t-test for unequal variances yielded a pvalue of 0.0594, thus the difference in the two means is significant (alpha of 0.06)
but not to the 0.05 level set by the researcher (See Table 16).

Table 16
Tier 2: ParadigmHealth to OSHPD: ALOS Comparison
Statistics

t-test procedure
Lower CL
Mean

Mean

25.247
22.518
-0.79

25.684
24.103
1.5804

26.121
25.689
3.9511

Minimum

Maximum

Variable

Dataset

N

ALOS
ALOS
ALOS

OSHPD
Paradigm
Diff (1-2)

3970
137

Variable

Dataset

Std Err

ALOS
ALOS
ALOS

OSHPD
Paradigm
Diff (1-2)

0.2229
0.8017
1.2092

Upper CL Lower CL
Mean Std Dev

13.621

T-Tests
Variable

Method

Variances

ALOS
ALOS

Pooled
Satterthwaite

Equal
Unequal

OF

t Value

Pr > I t I

4105
158

1.31
1.90

0.1913
0.0594

Equality of Variances
Variable

Method

ALOS

Folded F

Num OF

Den OF

F Value

Pr> F

3969

136

2.24

< .0001

Std Dev
14.045
9.3833
13.916

Upper CL
Std Dev

14.223
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ParadigmHealth to OSHPD analysis - tier 3. For Tier 3, the mean ALOS
of the ParadigmHealth dataset was 88.102 days, 6.362 days greater than the
mean ALOS for the OSHPD dataset (81.74 days). The F-test resulted in a pvalue of 0.0006 and the resulting Satterthwaite t-test for unequal variances
yielded a p-value of < 0.0001, thus the difference in the two means is significant
(See Table 17).

Table 17
Tier 3: ParadigmHealth to OSHPD: ALOS Comparison
t~test

Statistics

procedure

Variable

Dataset

ALOS
ALOS
ALOS

OSHPD
Paradigm
Diff (1-2)

Variable
ALOS
ALOS
ALOS

N

Lower CL
Mean

82.799
90.409

~9.535

81.74
88.102
-6.362

Dataset

Std Err

Minimum

Maximum

OSHPD
Paradigm
Diff (1-2)

0.5393
1.161
1.6167

759
90

80.682
85.795

Mean

Upper CL Lower CL
Mean Std Dev

~3.189

Std Dev

13.843

T~Tests

Variable

Method

Variances

ALOS
ALOS

Pooled
Satterthwaite

Equal
Unequal

Pr > I t

I

OF

t Value

847
131

-3.94
-0.04

< .0001
< .0001

Equality of Variances
Variable

Method

ALOS

Folded F

Num OF

Den OF

F Value

Pr > F

758

89

1.82

< .0006

14.858
11.014
14.502

Upper CL
Std Dev

15.227
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ParadigmHealth to OSHPD analysis - tier 4. For Tier 4, the mean ALOS
of the ParadigmHealth dataset was 41.781 days, 7.116 days greater than the
mean ALOS for the OSHPD dataset (34.665 days). The F-test resulted in a pvalue of 0.0026 and the resulting Satterthwaite t-test for unequal variances
yielded a p-value of < 0.0001, thus the difference in the two means is significant
(See Table 18).

Table 18
Tier 4: ParadigmHealth to OSHPD: ALOS Comparison
Statistics

t-test procedure
Lower CL
Mean

Mean

33.708
39.12
-10.33

34.665
41.781
-7.116

35.621
44.443
-3.901

Minimum

Maximum

Variable

Dataset

N

ALOS
ALaS
ALas

OSHPD
Paradigm
Diff (1-2)

2274
215

Variable

Dataset

Std Err

ALOS
ALaS
ALOS

aSHPD
Paradigm
Diff (1-2)

0.4877
1.3503
1.6396

Upper CL Lower CL
Mean Std Dev

22.258

T-Tests
Variable

Method

Variances

ALas
ALaS

Pooled
Satterthwaite

Equal
Unequal

Pr > I t I

OF

t Value

2487
273

-4.34
-4.96

< .0001
< .0001

Equality of Variances
Variable

Method

ALOS

Folded F

Num OF

Den DF

F Value

Pr > F

2273

214

1.38

< .0026

Std Dev
23.256
19.799
22.979

UpperCL
Std Dev

23.636
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Summary of findings for tiered comparisons. In the first two Tiers, the
ParadigmHealth ALOS was found to be lower than the aSHPD ALaS. For Tier
1, the ParadigmHealth ALOS was lower by 0.08 days (ParadigmHealth n = 90).
For Tier 2, the ParadigmHealth ALaS was lower by 1.58 days ParadigmHealth n

=137).

Based upon the F-test and t-test findings, neither of these differences in

the two means could be shown to be statistically significant.
For Tier 3, the ParadigmHealth ALaS was higher than the aSHPD ALaS
by 6.36 days, a significant difference of means within this Tier comparison
(ParadigmHealth n

=90).

For Tier 4, the ParadigmHealth ALaS was higher than

the OSHPD ALaS by 7.12 days (ParadigmHealth n = 215). Based upon the Ftest and t-test findings, both of these differences in the two means were shown to
be statistically significant (p-values for the Satterthwaite t-test were < 0.0001 in
both Tier 3 and Tier 4).
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OSHPD to MillimanUSA analysis - tier 1. For Tier 1, the mean ALOS of the
OSHPD dataset was 12.759 days, 3.5297 days less than the mean ALOS for the
MillimanUSA dataset (16.288 days). The F-test resulted in a p-value of < 0.0001
and the resulting Satterthwaite t-test for unequal variances yielded a p-value of <
0.0001 , thus the difference in the two means is significant (See Table 19).

Table 19
Tier 1: OSHPD to MillimanUSA: ALOS Comparison
Statistics

t-test procedure
LowerCL
Mean

Mean

16.139
12.457
3.172

16.288
12.759
3.5297

16.438
13.061
3.8874

Dataset

Std Err

Minimum

Maximum

Milliman
OSHPD
Diff (1-2)

0.0762
0.1540
0.1825

Variable

Dataset

ALOS
ALOS
ALOS

Milliman
OSHPD
Diff (1-2)

Variable
ALOS
ALOS
ALOS

N
93194
19002

Upper CL Lower CL
Mean Std Dev

Std Dev

22.834

T-Tests
Variable

Method

Variances

ALOS
ALOS

Pooled
Satterthwaite

Equal
Unequal

Pr > I t

I

DF

t Value

11E4
29E3

19.34
20.54

< .0001
< .0001

Equality of Variances
Variable

Method

ALOS

Folded F

Num OF

Den OF

F Value

Pr> F

93193

19001

1.2

< .0001

23.259
21.233
22.928

UpperCL
Std Dev

23.023
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OSHPD to MillimanUSA analysis - tier 2. For Tier 2, the mean ALOS of the
OSHPD dataset was 25.684 days, 1.6776 days less than the mean ALOS for the
MillimanUSA dataset (27.361 days). The F-test resulted in a p-value of < 0.0001
and the resulting Satterthwaite t-test for unequal variances yielded a p-value of <
0.0001, thus the difference in the two means is significant (See Table 20).

Table 20
Tier 2: OSHPD to MillimanUSA: ALOS Comparison
Statistics

t-test procedure
LowerCL
Mean

Mean

27.203
25.247
1.1425

27.361
25.684
1.6776

27.519
26.121
2.2128

Minimum

Maximum

Variable

Dataset

N

ALOS
ALOS
ALOS

Milliman
OSHPD
Oiff (1-2)

42732
3970

Variable

Dataset

Std Err

ALOS
ALOS
ALOS

Milliman
OSHPO
Oiff (1-2)

0.0806
0.2229
0.2730

Upper CL Lower CL
Mean Std Dev

Std Dev

16.35

T-Tests
Variable

Method

Variances

ALOS
ALOS

Pooled
Satterthwaite

Equal
Unequal

Pr > I t

I

OF

t Value

47E3
5067

6.14
7.08

< .0001

< .0001

Equality of Variances
Variable

Method

ALOS

Folded F

Num OF

Den DF

F Value

Pr > F

42731

3969

1.41

< .0001

16.661
14.045
16.455

Upper CL
Std Dev

16.561
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OSHPD to MillimanUSA analysis - tier 3. For Tier 3, the mean ALaS of
the aSHPD dataset was 81.74 days, 14.002 days less than the mean ALaS for
the MillimanUSA dataset (95.742 days). The F-test resulted in a p-value of <
0.0001 and the resulting Satterthwaite t-test for unequal variances yielded a pvalue of < 0.0001, thus the difference in the two means is significant (See Table
21 ).

Table 21
Tier 3: OSHPD to MillimanUSA: ALOS Comparison
Statistics

t-test procedure
Lower CL
Mean

Mean

95.309
80.682
12.42

95.742
81.74
14.002

96.175
82.799
15.584

Minimum

Maximum

Variable

Dataset

N

ALOS
ALOS
ALOS

Milliman
OSHPD
Diff (1-2)

9777
759

Variable

Dataset

Std Err

ALas
ALas
ALas

Milliman
OSHPD
Diff (1-2)

0.2209
0.5393
0.8071

Upper CL Lower CL
Mean Std Dev

Std Dev

21.135

T-Tests
Variable

Method

Variances

ALOS
ALOS

Pooled
Satterthwaite

Equal
Unequal

Pr > I t

I

OF

t Value

11E3
1032

17.35
24.03

< .0001
< .0001

Equality of Variances
Variable

Method

ALOS

Folded F

Num DF

Den DF

F Value

Pr> F

9776

758

2.16

< .0001

21.847
14.868
21.42

Upper CL
Std Dev

21.713
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OSHPD to MillimanUSA analysis - tier 4. For Tier 4, the mean ALaS of
the aSHPD dataset was 34.665 days, 7.3134 days greater than the mean ALaS
for the MillimanUSA dataset (41.978 days). The F-test resulted in a p-value of <
0.0001 and the resulting Satterthwaite t-test for unequal variances yielded a pvalue of < 0.0001 , thus the difference in the two means is significant (See Table

22).
Table 22
Tier 4: OSHPD to MillimanUSA: ALOS Comparison
Statistics

t-test procedure

N

Mean

41.596
33.708
6.0399

41.978
34.665
7.3134

42.36
35.621
8.5868

Minimum

Maximum

Variable

Dataset

ALOS
ALOS
ALOS

Milliman
OSHPD
Diff (1-2)

Variable

Dataset

Std Err

ALOS
ALOS
ALOS

Milliman
OSHPD
Diff (1-2)

0.1948
0.4877
0.6497

23943
2274

Upper CL Lower CL
Mean Std Dev

LowerCL
Mean

Std Dev

29.356

T-Tests
Variable

Method

Variances

ALOS
ALOS

Pooled
Satterthwaite

Equal
Unequal

Pr > I t

I

DF

t Value

26E3
3049

11.26
13.93

< .0001
< .0001

Equality of Variances
Variable

Method

ALOS

Folded F

Num DF

Den DF

F Value

Pr > F

23942

2273

1.68

< .0001

30.141
23.256
29.608

Upper CL
Std Dev

29.863
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Summary of findings for tiered comparisons. In each of the four Tiers, the
OSHPD ALOS was found to be lower than the MillimanUSA ALOS. For Tier 1,
the OSHPD ALOS was lower by 3.52 days (OSHPD n
OSHPD ALOS was lower by 1.67 days (OSHPD n

=19,002).

=3,970).

For Tier 2, the

For Tier 3, the

OSHPD ALOS was lower by 14.002 days, the largest difference of means within
this Tier comparison (OSHPD n = 759). For Tier 4, the OSHPD ALOS was lower
by 7.31 days (OSHPD n = 2,274). Based upon the F-test and t-test findings, the
differences in the two means was statistically significant (all p-values for the
Satterthwaite t-test were < 0.0001) in all four Tiers.
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Aggregate tier analysis. The ALaS of the ParadigmHealth dataset is

lower than the ALaS of the MillimanUSA dataset across all four Tiers. The ALaS
of the ParadigmHealth dataset is also lower than the ALaS for the aSHPD
dataset for Tier 1 and Tier 2. The reverse is true for Tier 3 and Tier 4 in which
the aSHPD ALaS is lower. The ALaS of the aSHDP dataset is lower than the
ALas of the MillimanUSA dataset across all four Tiers (See Figure 3).

Tiered T -test Comparison
100
90
80
~

70

~

.c

60
50

g'

40

\t-

...o
(1)

30

..J

20
10

o
4
1

2

3

4

UJ OSHPD

12.759

25.684

81.740

34.665

Wl Paradigm

12.676

24.103

88.102

41.781

fZJ Milliman

16.288

27.361

95.742

41.978

Figure 3: ALOS Comparison by Tiers: All Datasets

None of the Tier comparisons between ParadigmHealth and MillimanUSA
were shown to be statistically significant. In comparing the Tier groups of the
aSHPD dataset and the ParadigmHealth dataset, the differences
in mean ALaS
,
for Tiers 3 and 4 are statistically significant. In comparing the Tier groups of the
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OSHPD dataset and the MillimanUSA dataset, the differences in mean ALOS for
all four Tiers are statistically significant. Using the ParadigmHealth ALOS as the
baseline, Figure 4 presents the relative comparison of the mean ALOS for each
of the three datasets.

Tiered T -test (Paradigm Base)
8

Q)

In

6

ns

.c
~

0

a;
.c

ens

4

2

In

~

ns

0

"'C

I

Q)

u (2)
c:
ns
·c
ns (4)

>

en
0

...J

(6)

(8)

1

2

3

4

Tier

1111 Milliman III OSHPD

I

Figure 4: ALOS Difference: ParadigmHealth as Baseline

Comparison of the ParadigmHealth and MillimanUSA Datasets by APR-DRG

There were 82 APR-DRG categories within which both the ParadigmHealth
dataset and the MillimanUSA dataset had neonatal cases. Of these, 20
categories had only one ParadigmHealth observation. While they were included
in the overall study for grouping purposes, those individual APR-DRGs were not
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compared. The remaining 62 APR-DRG categories were individually compared
and grouped by DRG birthweight categories. Following the t-test procedure,
twelve APR-DRGs appeared to have significant differences of the two means
and are reported in Table 23.

Table 23
Comparison of ParadigmHealth & MillimanUSA by APR-DRG
APR-DRG

Parad igm Health

MillimanUSA

Difference

~-value

Paradigm n

593/3

64.83
38.00
40.25
32.00
15.85
10.00
8.00
9.33
27.90
19.40
10.00
15.00

76.43
59.45
69.01
18.55
12.97
10.72
15.20
16.25
49.93
37.61
11.78
25.95

(11.60)
(21.45)
(28.76)
13.45
2.88
(0.72)
(7.20)
(6.92)
(22.03)
(18.21)
(1.78)

0.0248
0.0336
0.0150
0.0249
0.0164
0.0001
0.0006
0.0009
0.0023
0.0030
0.0001
0.0355

12
4
4
2
27
2
4
6
10
5
2

601/4
610/4
612/1
614/1

622.1
626/2
626/3
630/4
634/4
635/3
639/3

{10.95}

Milliman n

8

1,219
853
297
1,133
10,842
1,527
1,191
2,037
600
2,104
1,995
989

Of these twelve APR-DRGs, all were ruled as inconclusive tests due to relatively
small ParadigmHealth sample size (n < 25) except for APR-DRG 614, severity
level 1. For this APR-DRG, the mean ALOS of the ParadigmHealth dataset was
15.852 days, 2.884 days greater than the mean ALOS for the MillimanUSA
dataset (12.968 days).

Comparison of the ParadigmHealth and OSHPD Datasets by APR-DRG
There were 81 APR-DRG categories within which both the ParadigmHealth
dataset and the OSHPD dataset had neonatal cases. Of these, 33 categories
had only one ParadigmHealth observation. While they were included in the
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overall study for grouping purposes, those individual APR-DRGs were not
compared. The remaining 48 APR-DRG categories were individually compared
and grouped by DRG birthweight categories. Following the t-test procedure,
eight (8) APR-DRGs appeared to have significant differences of the two means
are reported in Table 24.
Table 24
Comparison of ParadigmHealth & OSHPD by APR-DRG
~-value

Paradigm n

(22.22)
(7.37)
2.45

0.0415
0.0078
0.0451

4
3
27

11.11

(1.11 )

0.0047

2

158

8.94
8.56
17.03
6.94

1.06
8.44
12.98
6.06

0.0008
0.0036
0.0468
0.0030

2
3
3

264
1,221
40
1,457

APR-DRG

Paradigm Health

OSHPD

60114
611/3
614/1

38.00
23.67
15.85

60.22
31.03
13.40

622/1

10.00

635/3
639/2
639/4
640/3

10.00
17.00
30.00
13.00

Difference

Milliman n

3

106
93
1,055

Of the eight, all were ruled as inconclusive due to relatively small
ParadigmHealth sample size (n < 25) except for APR-DRG 614, severity level 1.
For APR-DRG 614, severity level 1, the mean ALOS of the ParadigmHealth
dataset was 15.852 days, 2.451 days greater than the mean ALOS for the
OSHPD dataset (13.401 days).

Analysis of Range of Length

~f Stay

An analysis was performed of the ParadigmHealth, OSHPD, and
MillimanUSA datasets to evaluate the range of length of stay represented in each
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of the birthweight groups. For each of the birthweight groups, the lowest LOS
and the Highest LOS was recorded. These findings are shown in Table 25.

Analysis of length of stay range for infants with ECMO procedures. For
the ECMO Category, the ParadigmHealth total LOS range was 45 days, lower
than the range for both the MillimanUSA dataset (367 days) and the OSHPD
dataset (53 days). Both the MillimanUSA and the OSHPD datasets had cases
with shorter LOS with the minimum LOS point being in the MillimanUSA dataset
(6 days). The OSHPD dataset's maximum LOS point was the lowest (53 days)
and the MillimanUSA dataset's maximum LOS point was the greatest (373 days).

Analysis of length of stay range for infants with birlhweight < 750 grams.
Within this category, the ParadigmHealth total LOS range was 115 days, lower
than the range for both the MillimanUSA dataset (832 days) and the OSHPD
dataset (229 days). Both the MillimanUSA and the OSHPD datasets had cases
with shorter LOS with the minimum LOS point being in the OSHPD dataset (11
days). The ParadigmHealth dataset's maximum LOS point was the lowest (180
days) and the MillimanUSA dataset's maximum LOS point was the greatest (884
days).

Analysis of length of stay range for infants with birlhweight 750 - 999
grams. Within this category, the ParadigmHealth total LOS range was 170 days,
lower than the range for both the MillimanUSA dataset (334 days) and the
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OSHPD dataset (380 days). The OSHPD dataset had cases with shorter LOS
with the minimum LOS paint being 6 days. The ParadigmHealth dataset's
maximum LOS point was the lowest (206 days) and the OSHPD dataset's
maximum LOS point was the greatest (386 days).

Analysis of length of stay range for infants with birthweight 1000 - 1499
grams. Within this category, the ParadigmHealth total LOS range was 144 days,
lower than the range for both the MillimanUSA dataset (337 days) and the
OSHPD dataset (271 days). The OSHPD dataset had cases with shorter LOS
with the minimum LOS point being 5 days. The ParadigmHealth dataset's
maximum LOS point was the lowest (160 days) and the MillimanUSA dataset's
maximum LOS point was the greatest (354 days).

Analysis of length of stay range for infants with birth weight 1500 - 1999
grams. Within this category, the ParadigmHealth total LOS range was 65 days,
lower than the range for both the MillimanUSA dataset (560 days) and the
OSHPD dataset (187 days). The ParadigmHealth dataset had cases with shorter
LOS with the minimum LOS point being 4 days. The ParadigmHealth dataset's
maximum LOS point was also the lowest (69 days) and the MillimanUSA
dataset's maximum LOS point was the greatest (565 days).

Analysis of length of stay range for infants with birthweight 2000 - 2499
grams. Within this category, the ParadigmHealth total LOS range was 103 days,
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lower than the range for both the MillimanUSA dataset (468 days) and the
OSHPD dataset (198 days). The ParadigmHealth dataset had cases with shorter
LOS with the minimum LOS point being 3 days. The ParadigmHealth dataset's
maximum LOS point was also the lowest (206 days) and the MillimanUSA
dataset's maximum LOS point was the greatest (473 days).

Analysis of length of stay range for infants with birthweight > 2499 grams.
Within this category, the ParadigmHealth total LOS range was 130 days, lower
than the range for both the MillimanUSA dataset (508 days) and the OSHPD
dataset (159 days). Both the ParadigmHealth dataset and the OSHPD dataset
had cases with shortest LOS with the minimum LOS point being 5 days for each.
The ParadigmHealth dataset's maximum LOS point was also the lowest (135
days) and the MillimanUSA dataset's maximum LOS point was the greatest (514
days).
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Table 25
Comparison of LOS Ranges within Birlhweight Groups
Birthweight Category
ECMO

<750G
750 - 999G
1000-1499G
1500-1999G
2000-2499G
>2499G

Low LOS

34
6
13
65
52
11
36
38
6
16
17
5
4
5
5
3
5
5
5
6
5

High LOS

79
373
66
180
884
240
206
372
386
160
354
276
69
565
192
106
473
203
135
514
164

Range

45
367
53
115
832
229
170
334
380
144
337
271
65
560
187
103
468
198
130
508
159

Dataset
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD

Summary of findings. For each of the birthweight categories, the
ParadigmHealth dataset showed the smallest range in total length of stay. With
the exception of the ECMO category, the ParadigmHealth dataset also yielded
the lowest maximum length of stay point across the birthweight categories.
Within the ECMO category, the OSHPD dataset yielded the lowest maximum
length of stay point. A graphical display of these lengths of stay ranges is
provided in Figure 5.
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Figure 5: Total Length of Stay Range by Birthweight Category

v.

Discussion

There are numerous ideological and operational challenges involved in
attempting to impact the average length of stay for NICUs. In today's era of cost
containment and accountability for quality of care, any connection between
experience and patient outcome has far reaching implications for patients,
payers, and governmental agencies. Despite compelling evidence of the value of
highly specialized neonatal intensive care units, questions remain about the
proliferation of these units and the clinical processes that determine length of
stay (Doyle et aI., 1988; McLean et aI., 2002).
The objective of this study was to determine the effectiveness of
Paradigm Health's systematic care management (SCM) model in reducing both
the average length of stay (ALOS) for NICU cases and the range in NICU lengths
of stay. The initial test, a t-test of the overall datasets linked by DRG, revealed
that the ALOS of the ParadigmHealth dataset was 5.56 days lower than the
MillimanUSA dataset and was found to be statistically significant. When broken
into individual APR-DRGs, the ALaS for the ParadigmHealth dataset was below
the ALOS of either comparison group for the majority of the APR-DRGs. This
level of analysis resulted in very small sample sizes for each APR-DRG for the
ParadigmHealth dataset and the majority of the tests, while clearly showing a
lower ALaS for the ParadigmHealth dataset, were deemed inconclusive. One
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APR-DRG cell had a sufficient size to show statistical significance (the same cell
for both the MillimanUSA and OSHPD). Interestingly, this was a low severity
(severity 1) "other" category for a relatively large neonate (1500 - 1999 grams).
Within the birthweight Tier analysis (1000 gram increments), the ParadigmHealth
dataset revealed lower ALOS than the MillimanUSA dataset in all four Tiers. The
ParadigmHealth dataset showed lower ALOS than the OSHPD dataset for Tiers
1 and 2 but greater ALOS than the OSHPD dataset for Tiers 3 and 4. Only Tiers
3 and 4 of the ParadigmHealth to OSHPD comparison showed statistical
significance.
Perhaps the most revealing part of the study was the range of LOS
analyses. In all categories, the ParadigmHealth dataset revealed a lower range
of LOS than either the MillimanUSA dataset or the OSHPD dataset.
Interestingly, the ParadigmHealth dataset contains the greatest proportion of Tier
4 cases - the most medically complex neonates.
The researcher acknowledges that these findings are inconclusive when
one focuses only on the individual statistical tests. However, in looking at the
analyses in total, one can find clear evidence that the SCM approach indeed
reduces the range of length of stay for neonates. One can draw tentative
conclusions regarding the effectiveness of the SCM approach in reducing
average length of stay. The results are discussed in more detail below.
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Tests for Significance: Overall Comparison of ParadigmHealth to MillimanUSA
The first t-test procedure compared the means of the paradigmHealth
dataset and the MillimanUSA dataset grouped by DRG. The results of the t-test
revealed that the ALaS of the ParadigmHealth dataset was 5.59 days, on
average, lower than the MillimanUSA ALOS for DRG-matched neonates (t =
4.28, P < 0.0001). The mean differences between the ALOS reductions of the
ParadigmHealth and MillimanUSA samples ranged from 0 to 26 days with
greatest differences were in the extremely low birthweight group (those infants <
1000 grams) as shown in Figure 2. Interestingly, the difference in average length
of stay between the ParadigmHealth dataset and the MillimanUSA dataset
declines as birthweight increases until the final category (infants> 2500 grams).
These cases are primarily infants with seemingly normal birth weights but having
any number of congenital anomalies or other clinical complexities that cause an
admission to the NICU. In this area, ParadigmHealth's ALaS is well below the
MillimanUSA ALaS, similar to its performance with the lower birthweight infants.

Tests for Significance: Individual APR-DRG Comparisons
Following the overall comparison, additional t-test procedures were
completed comparing, by individual APR-DRG the mean of ParadigmHealth
dataset to the mean of the MillimanUSA dataset and the mean of the OSHPD
dataset. Given that this test was done by individual APR-DRG, it is not surprising
that the ParadigmHealth sample sizes for each become quite small (the total n
for ParadigmHealth is 532 and there are 132 APR-DRG categories). The
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purpose of this additional analysis was to both identify any trend that might exist
in discreet APR-DRGs and to further test for differences in the means that may
be shown to be significant.

ParadigmHealth and MillimanUSA analysis. There were 82 APR-DRG

categories within which both the ParadigmHealth dataset and the MillimanUSA
dataset had neonatal cases. Of these, 20 categories had only one
ParadigmHealth observation. While they were included in the overall study for
grouping purposes, those individual APR-DRGs were not compared. The
remaining 62 APR-DRG categories were individually compared. In 47 of the 62
APR-DRG categories, the ParadigmHealth ALOS was less than the MillimanUSA
ALaS. Following the t-test procedure, twelve APR-DRGs appeared to have
significant differences. All were ruled as inconclusive due to relatively small
ParadigmHealth sample size (n < 25) except for APR-DRG 614, severity level 1.
For this APR-ORG, the mean ALOS of the ParadigmHealth dataset was 15.852
days, 2.884 days greater than the mean ALaS for the MillimanUSA dataset
(12.968 days).
APR-DRG 614-1 is considered an "other" category of low severity
(severity 1). To score a severity 1 the birthweight is matched with only one
diagnostic or procedure code (indicating the absence of co-morbidities). In the
researcher's view, ParadigmHealth's caseload is more oriented to higher severity
infants and, even within such refined categories as the APR-DRG classification
system, differences in severity exist. It appears to be a bit of a'n aberration, in the
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researcher's view, that the "other" category is the one in which ParadigmHealth's
ALOS was higher and not within the categories in which a co-morbidity,
congenital anomaly or other clinical complexity is actually defined.

ParadigmHealth and OSHPD analysis. There were 81 APR-DRG
categories within which both the ParadigmHealth dataset and the OSHPD
dataset had neonatal cases. Of these, 33 categories had only one
ParadigmHealth observation. While they were included in the overall study for
grouping purposes, those individual APR-DRGs were not compared. The
remaining 48 APR-DRG categories were individually compared. In 32 of the 48
APR-DRG categories, the ParadigmHealth ALOS was less than the OSHPD
ALOS. Following the t-test procedure, eight APR-DRGs appeared to have
significant differences. All were ruled as inconclusive due to relatively small
ParadigmHealth sample size (n < 25) except for APR-DRG 614, severity level 1.
For APR-DRG 614, severity level 1, the mean ALOS of the ParadigmHealth
dataset was 15.852 days, 2.451 days greater than the mean ALOS for the
OSHPD dataset (13.401 days).
Oddly, the same APR-DRG was identified in the ParadigmHealth and
MillimanUSA comparison. In both instances, the ParadigmHealth ALOS is higher
than the comparison sample. This finding, in the researcher's view, lends
additional credibility to the logic given for this same difference in the
ParadigmHealth and MillimanUSA comparison.
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Tests for Significance: Tier Group Comparisons

The researcher then grouped the APR-DRGs into birthweight Tiers. (See
Appendix C for definition and specific APR-DRG assignments to Tiers.) There is
a relatively large difference in the proportion of cases for Tiers 3 and 4 within the
ParadigmHealth dataset in contrast to both comparison samples. Tier 3 includes
all infants weighing less than 1000 grams. This Tier represents 150/0 of the
ParadigmHealth dataset while comprising only 3% of the OSHPD dataset and
60/0 of the MillimanUSA dataset. Tier 4 includes the most medically complex
categories of infants (severity 4 and ECMO). Tier 4 represents 420/0 of the
ParadigmHealth dataset while comprising only 12% of the OSHPD dataset and
16% of the MillimanUSA dataset. These proportional findings, in the
researcher's view, validate the assertion made by ParadigmHealth the cases
managed by the SCM team tend to be the most medically complex neonates.

ParadigmHealth and MillimanUSA analysis. In each of the four Tiers, the

ParadigmHealth ALOS was found to be lower than the ALOS for the
MillimanUSA dataset. The findings of this analysis are consistent with the overall
comparison of the ParadigmHealth dataset and the MillimanUSA dataset. These
findings are consistent with the lower ALOS found within the ParadigmHealth
dataset across the majority of the APR-DRGs compared. Based upon the F-test
and t-test findings, these differences in the Tier group means could not be shown
to be statistically significant (p-values for the Satterthwaite t-test ranged from
0.2037 - 0.9749).
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ParadigmHealth and OSHPD analysis. In the first two Tiers, the
ParadigmHealth ALOS was found to be lower than the OSHPD ALOS. Based
upon the F-test and t-test findings, neither of these differences in the two means
could be shown to be statistically significant For Tier 3, the ParadigmHealth
ALOS was higher than the OSHPD ALOS by 6.36 days (ParadigmHealth n

=90).

For Tier 4, the ParadigmHealth ALOS was higher than the OSHPD ALOS by
7.12 days (ParadigmHealth n

=215).

Based upon the F-test and t-test findings,

both of these differences in the two means were shown to be statistically
significant (p-values for the Satterthwaite t-test were < 0.0001 in both Tier 3 and
Tier 4). Interestingly, the OSHPD dataset had the lowest proportion of extremely
low birthweight (infants < 1000 grams, Tier 3) and the lowest proportion of
severity 4 cases (only 12% of the OSHPD Dataset). These proportional
differences, in the researcher's view, largely explain the findings of the analysis
for Tier 3 and Tier 4. Another observation is that the OSHPD dataset is solely a
California dataset, a market known for much more aggressive case management
by health insurers and for having a greater supply of NICUs per capita that the
rest of the nation (Thompson et aI., 2002).

OSHPD and MillimanUSA analysis. In each of the four Tiers, the OSHPD
ALOS was found to be lower than the MillimanUSA ALOS. Based upon the Ftest and t-test findings, the differences in the two means was statistically
significant (all p-values for the Satterthwaite t-test were < 0.0001) in all four Tiers.
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Summary of findings. The ALOS of the ParadigmHealth dataset is lower
than the ALOS of the MillimanUSA dataset across all four Tiers. The ALOS of the
ParadigmHealth dataset is lower than the ALOS for the OSHPD dataset for Tier
1 and Tier 2. The reverse is true for Tier 3 and Tier 4 in which the OSHPD ALOS
is lower. The ALOS of the OSHDP dataset is lower than the ALOS of the
MillimanUSA dataset across all four Tiers. None of the Tier comparisons
between ParadigmHealth and MillimanUSA were shown to be statistically
significant. In comparing the Tier groups of the OSHPD dataset and the
ParadigmHealth dataset, the differences in mean ALOS for Tiers 3 and 4 are
statistically significant. In comparing the Tier groups of the OSHPD dataset and
the MillimanUSA dataset, the differences in mean ALOS for all four Tiers are
statistically significant.

Range of LOS Analysis
Table 25 reflects the findings of the researcher in comparing the range of
length of stay (LOS) between the ParadigmHealth dataset and the two
comparison samples. These findings are, perhaps, the most revealing of the
entire study. The APR-DRGs representing the smaller birthweight groups
demonstrate greater spread in the range of LOS than those representing the
larger birthweight groups.
For each of the birthweight categories, the ParadigmHealth dataset
demonstrated the lowest range in total length of stay. With the exception of the
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ECMO category, the ParadigmHealth dataset yielded the lowest maximum length
of stay point across the birthweight categories. Within the ECMO category, the
OSHPD dataset yielded the lowest maximum length of stay point. The predictive
modeling tools used by ParadigmHealth to quantify neonatal risk factors,
establish and predict the probability of complications, and the management tools
used to mitigate these risks may well be the drivers for this significant difference
in the range of LOS. Clearly, this is an area that warrants further study.
Table 26
Range of Variability in Total LOS: ParadigmHealth, OSHPD, and MillimanUSA

Birthweight Category
ECMO

<750G
750 - 999G
1000-1499G
1500-1999G
2000-2499G

Low LOS

High LOS

Range

34
6
13
65
52
11
36
38
6
16
17
5
4
5
5
3

79
373
66
180
884
240
206
372
386
160
354
276
69
565
192
106
473
203
135
514
164

45
367
53
115
832
229
170
334
380
144
337
271
65
560
187
103
468
198
130
508
159

5

>2499G

5
5
6
5

Dataset
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
Paradigm
Milliman
OSHPD
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Readmission Following NICU Discharge
A concern may be raised that the achievement of ALOS reductions could
be detrimental to the clinical quality of the outcomes. This could be evidenced by
efficient discharges, but a higher than predicted number of readmissions.
ParadigmHealth's outcome-based management process includes ongoing
management for a minimum of 30 days after discharge from the NICU and if a
readmission occurs, ParadigmHealth has a financial responsibility for that rehospitalization. To confirm that ParadigmHealth achieved its reduction in LOS
without sacrificing quality through re-hospitalizations, a comparison was made of
the incidence of re-hospitalizations within the first 30 days post discharge from
the NICU between ParadigmHealth and an APR-DRG matched sample.
As the MillimanUSA database did not include post-discharge follow-up at
30 days, an alternative comparison sample was obtained from the OSHPD
database managed by Dr. Phibbs at the Stanford office of the National Bureau of
Economic Research. The results of the comparison of the severity-matched
groups revealed that there was no difference in the rate of re-admissions
between the two groups. The percentage of re-admissions was 60/0 percent for
both groups. While there were no differences in the rate of readmissions, the
average LOS of the Paradigm readmissions was 1.6 days shorter than the
comparison sample. This may be due to the fact that ParadigmHealth was also
accountable for the management of the readmission as well.
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Pro forma Calculation of Hospital Charges
A pro forma calculation of the reduced hospital charges associated with a
reduction in ALaS, using MillimanUSA national data, indicates an average
reduction of between $15,306 and $24,222. This reduction in particular is
dramatic for the most complex of the neonates, those under 750 grams
birthweight, who show a LOS reduction of 8 days with pro-forma savings of
approximately $36,790. Such reductions are relevant to the payer (not the
provider) as they represent reductions in facility charges corresponding to a
reduction in NICU patient LOS and do not necessarily reflect a reduction in
provider cost for the episode of care.

Conclusions
Following the specific aims identified in chapters 1 and 3, there were two
significant findings identified in this research project and supported by the data
presented in Chapter Four:
1. To determine whether the SCM process of management is associated
with significant reductions in the average length of stay (ALOS) of
complex, high-risk neonates during their initial NICU hospitalization.
The researcher acknowledges that these findings are inconclusive when one
focuses only on the individual statistical tests. However, in looking at the
analyses in total, one can draw tentative conclusions regarding the effectiveness
of the SCM approach in reducing average length of stay. The overall
comparison of the ParadigmHealth dataset and the MillimanUSA dataset

105

revealed that ParadigmHealth's ALOS was 5.56 days lower. While the more
refined tests were largely inconclusive due to small sample sizes within a single
APR-DRG, the ParadigmHealth dataset yielded lower ALOS for the majority of
the APR-DRGs tested.
2. To determine whether SCM is effective in reducing the range of NICU
lengths of stay.
Across all birthweight categories, the ParadigmHealth dataset showed the least
range in total length of stay (defined as maximum LOS - minimum LOS). With
the exception of one category, ECMO, the ParadigmHealth dataset also yielded
the lowest maximum length of stay point across the birthweight categories.
Within the ECMO category, the OSHPD dataset yielded the lowest maximum
length of stay point. In the researcher's view, this is a highly relevant finding and
an area for additional study as a number of predictive modeling tools are used
within the SCM process to predict and mitigate potential problems and risks.

Research Question Revisited

In comparing the ParadigmHealth dataset to the MillimanUSA dataset, the
research presented here provides support to reject the H1 research hypotheses
presented in chapters 1 and 3. The overall comparison of the ParadigmHealth
and MillimanUSA datasets yielded a 5.56 day lower ALOS for the
ParadigmHealth dataset. Yet while all the Tier groups resulted in a lower ALOS
for the ParadigmHealth dataset, the findings could not be shown to be
statistically significant. This finding was repeated within the individual APR-DRG
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comparisons in which, for a majority of the cases, a lower ALOS was found for
the ParadigmHealth dataset but the relatively small sample size prohibited the
comparison from achieving statistical significance. Accordingly, the researcher
has rejected the research hypothesis and accepted the corresponding null
hypotheses presented based on the following findings:

H 1:

There is no evidence that ParadigmHealth's Systematic Care
Management (SCM) process results in a reduction in ALOS (and
therefore, the null hypothesis is accepted).

In comparing the ParadigmHealth dataset to the MillimanUSA dataset, the
research presented here provides support to accept the H2 research hypotheses
presented in chapters 1and 3. Accordingly, the researcher has rejected the null
hypothesis presented based on the following findings:

H2:

There is evidence that the SCM process reduces the range of
patient length of stay in the high-risk neonate (NICU) population
(and therefore the null hypothesis is rejected).

In comparing the ParadigmHealth dataset to the OSHPD dataset, the
research presented here provides no support to accept the H1 research
hypotheses presented in chapters 1and 3. Two Tier groups resulted in a higher
ALOS for the ParadigmHealth dataset; the differences of which were statistically
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significant. While Tier groups 1 and 2 resulted in a lower ALaS for the
ParadigmHealth dataset, the findings could not be shown to be statistically
significant. This finding was repeated within the individual APR-DRG
comparisons in which, for a majority of the cases, a lower ALaS was found for
the ParadigmHealth dataset but the relatively small sample size prohibited the
comparison from achieving statistical significance. Accordingly, the researcher
has rejected the research hypothesis and accepted the corresponding null
hypotheses presented based on the following findings:

H1:

There is no evidence that ParadigmHealth's Systematic Care
Management (SCM) process results in a reduction in ALaS (and
therefore, the null hypothesis is accepted).

In comparing the ParadigmHealth dataset to the aSHPD dataset, the
research presented here provides support to accept the H2 research hypotheses
presented in chapters 1and 3. Accordingly, the researcher has rejected the null
hypothesis presented based on the following findings:

H2:

There is evidence that the SCM process reduces the range of
patient length of stay in the high-risk neonate (NICU) population
(and therefore the null hypothesis is rejected).
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Implications for NICU Management
The results of this study are largely inconclusive as to whether the
application of ParadigmHealth's Systematic Care Management (SCM) model
(Bryant, 2002; Gardner, 1999) is associated with reductions in NICU lengths of
stay for severity-matched neonates. The overall comparison of the
ParadigmHealth dataset and the MillimanUSA dataset revealed a 5.56 day lower
ALOS for the ParadigmHealth dataset (t = 4.28, P < .0001). Within the individual
APR-DRG groups, the relatively small numbers of infants allow only tentative
conclusions. Given that a majority of the cases reviewed showed a lower ALaS
for the ParadigmHealth dataset, additional cases may provide more conclusive
evidence in the future.
Perhaps the most significant finding was the marked reduction in the
range of LOS within the ParadigmHealth dataset. The SCM process includes
predictive modeling tools used by ParadigmHealth to quantify neonatal risk
factors to establish and predict the risk and probability of neonatal complications.
In addition the SCM process provides both clinical- and data-oriented
management tools used to mitigate these risks. These aspects of the SCM
model may well be the drivers for this significant difference in the range of LOS.
This is an area that warrants further study.
The strength of the findings is supported by the wide geographic spread of
the population of infants studied, which represents most regions of the
continental United States, as well as the extended three-year period over which
the data were gathered. The results are strengthened when contrasted with
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general experience of increasing average lengths of stay (ALOS) as the number
and survival of very low birthweight infants continues to increase.
From the view of the health care payer (or purchaser) a reduction in ALOS
may result in a reduction in total costs incurred for the NICU experience
(Gardner, 1999; McLean et aI., 2002). The exact degree and nature of such cost
reductions would be predicated on the payer having a per diem reimbursement
structure with the treating facility so that a reduction in LOS has a corresponding
reduction in dollars incurred.
From the view of the health care provider (institution or practitioner) a
reduction in ALaS may have no impact in the total costs incurred for the NICU
experience. Providers often suggest that true costs of care are, in fact, nonlinear and greatest in the first few days or weeks of care. Kaufman and Shepard
(1982) first reported this non-linear and inverse relationship between a neonatal
intensive care patient's day of life and the quantity of hospital resources required
to provide their care. Further research is required to determine if this
phenomenon continues to exist now some twenty years later.

Limitations

Several limitations of this study should be noted. First, several factors affect
the incidence of low birth weight infants, their outcomes, and the resulting length
of stay_ These factors, the measurement of which is challenging, include
individual characteristics such as ethnicity, gestational age, intrauterine growth
retardation, maternal smoking, and education (Bronstein, Carpilouto, Carlo,
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Haywood, & Goldenberg, 1995; Demisse et aI., 1997; Lightwood, Phibbs, &
Glantz, 1999). In addition, other differences that affect infant outcomes but are
not reliably measured include poverty, local interpretations of the level of
intensive care provided, intensive care unit volume and practice style, and place
of delivery (Bird & Bauman, 1998; Crosse, Alder, Ostbye, & Campbell, 1997;
Kirby, 1996; Phibbs, Bronstein et aI., 1996; Powell, Holt, Hickok, Easterling, &
Connell, 1995; Yeast, Poskin, Stockbauer, & Shaffer, 1998).
This study effort was limited by the nature of the research datasets used in
this analysis. In order to control for facility coding and billing practices of
providers within its database, the MillimanUSA dataset excludes neonatal deaths
and infants discharged from the NICU within 5 days of admission, as such short
stays are not representative of the general neonatal intensive care population.
The ParadigmHealth sample size, while greater than 500 cases, was
relatively small when sorted by the various APR-DRG categories (132 categories
in all). In addition to the twelve APR-DRG mean differences that were
considered inconclusive due to relatively small sample size (n < 25), additional
mean differences may be relevant but cannot be shown to be significant due to
the limitations of the ParadigmHealth cases within those APR-DRGs.
In addition, while nationally recognized as the best severity adjustment
parameter currently available in neonatal care, the APR-DRG weighted score for
a patient may be influenced by human error in the classification and recording of
secondary diagnosis and procedure codes.
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This research assumes the presence of nationally accepted evidencebased protocols for the care of high-risk infants in neonatal intensive care. The
real world variability in neonatal intensive care practices (and their resultant
outcomes) across facilities, regions and the Nation present a limitation and
challenge to this research effort.
Finally, use of the MillimanUSA dataset and the California OSHPD dataset
as a convenience sample for this study, while robust, may not represent the
actual practice patterns of the nation's NICUs. As such, conclusions drawn for
this study may have limited applicability or clinical relevance to nation-wide
neonatal intensive care practice.

Opportunities for Future Research

This study has provided preliminary but inconclusive information about the
effect of physician collaboration in providing medical services for the neonatal
population. A follow-up study involving additional ParadigmHealth cases could
strengthen the case for SCM. A future study could further quantify the utility of
SCM by determining the variance in patient emergency room visits and readmission rates following NICU discharge for each of these datasets. In
addition, future study is warranted to determine the relationship, if any, between
a reduction in NICU length of stay and a corresponding reduction in provider
defined or payer defined costs.
An additional research opportunity exists to determine the economic
impact to both the provider and purchaser of NICU services by/realizing a
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reduction in NICU lengths of stay. Further study might contrast the application of
SCM to small, community NICUs to those in larger, tertiary (or teaching)
institutions.
Additional research specifically focused on the differences in the range of
LOS identified in this study between the ParadigmHealth dataset and both
comparison samples may reveal opportunities to use predictive modeling as a
basis for further collaboration between providers and payers for this highly
complex and costly population.

Summary
It has long been recognized in the public policy domain that a crisis
situation is usually necessary, but not sufficient, to ensure significant policy
action (Schwartz, 1998). Brown suggested two other political conditions
prerequisite for action to occur: (1) A "call to arms" by policy makers who are
persuaded that the problem is urgent, and (2) Consensus on a defined, easily
understood strategic model to address the problem (Gardner, 1999).
Over the past decade, the U.S. health care delivery system has been
undergoing an almost perpetual process of reconfiguring various provider
arrangements and financing structures. Such fundamental, ongoing
organizational changes have affected virtually all populations. The crisis
situation derives from a growing concern about the ability of constantly evolving
organizational models of care delivery to preserve health care access and quality
while containing costs, especially for vulnerable populations. ~i
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Nevertheless, there is a consensus among vested parties that the
objectives of a health care system should include the following:
1. To manage health care costs,
2. To improve access to care,
3. To maintain or improve quality of care, and
4. To establish equitable priorities for allocating finite health care
resources (Gardner, 1999).
Yet the saga of neonatology is emblematic of how a market-driven health
care system with inadequate public planning can produce too much of a good
thing - the overgrowth of this specialty likely comes at the expense of underinvestment in less glamorous primary care and public health services that avert
poor birth outcomes (Grumbach, 2002). NICUs are economically successful
because they are medically successful (Lantos, 2001). NICUs are profit-making
centers for hospitals, commanding high payments from private and public
insurance plans. One of the few investor-owned physician groups to remain
financially successful is in the business of providing neonatal services through
more than 600 employed neonatologists in over 190 NICUs across the U.S. and
earned more than $68.8 million in net profits for investors in 2002 (Investors,
2003).
While not conclusive, this study argues that a SCM approach to the
management of NICU patients has a compelling potential to satisfy these core
objectives. The foundation of the SCM approach has the capability to transform
the process of NICU care through evidence-based decision-making, by iteratively
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examining relationships between process and outcome, eliminating inappropriate
services, and enhancing both the efficiency and the outcome of the care that is
delivered (Cope, Bryant et aI., 2001). SCM has the potential to resolve three of
the most salient concerns about the effectiveness of managed care: lack of
scientific evidence by which to base decisions about alternative clinical
pathways; appropriateness and timelines of services rendered; and fiscal
accountability, particularly germane to catastrophic injuries and conditions
(McLean et aI., 2002).
While many attempts have been made to restrain health care costs
rationally while maintaining quality of care, skepticism still abounds about the
ability of traditional managed care models to meet these objectives. More and
more, if market considerations displace the professional authority of physicians
(Silver, 1997), there will be greater need for rigorously collected data on costs
and effectiveness by which to base, and evaluate, clinical decisions and selection
of providers.
The history of public health legislation indicates that public policy will
respond when the preponderance of evidence suggests a clear and pressing
need and a clearly defined solution. The literature review (chapter 2) documents
that a clear and pressing need has been established and the findings of this
study suggest that systematic care management (SCM) may prove to be a
solution (with additional case volume). Systematic care management is a model
worthy of review by insurers, providers, payers and consumers alike. It is also an
area for further study and research by the academic community.
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Appendix A
Definition of Terms

ADC - Average daily census (patient volume/day).
Assessment - An evaluation and data gathering performed by the
ParadigmHealth team. Demographic information; a description of the patient's
history of injury or disability, current medical, functional and psychosocial status;
and pre-morbid information is collected and analyzed.
APR-DRG Classification System - a patient classification system that was
developed by 3M Health Information Systems and modeled after the All Patient
DRG system. This classification system uses hospital patient discharge data and
computer-based logic to assign patients to severity of illness and risk of mortality
classes so they can be accurately compared in terms of length of stay, resource
consumption, and outcomes.
Birth-weight Classifications - There is no universal agreement on birthweight classification. The commonly accepted definitions follow:
Macrosomia - 4000 grams or more.
Normal Birth Weight - 2500 - 3999 grams.
Low Birth Weight - Less than 2500 grams.
Very Low Birth Weight - Less than 1500 grams.
Extremely Low Birth Weight - Less than 1000 grams.
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Clinical Practice Guidelines (CPGs) - Systematically developed
statements to assist practitioner and patient decisions about appropriate health
care for specific clinical circumstances (Field & Lohr, 1990; Kurec, 1996).
Diagnostic Related Groups (DRGs) - Classification system developed at
Yale University using 383 major diagnostic categories based on the ICD-9 codes.
A system for determining case mix, used for payment under Medicare's PPS and
by some other payers. The DRG system classifies patients into groups based on
the principal diagnosis, type of surgical procedure, presence or absence of
significant co-morbidities or complications, and other relevant criteria. DRGs are
intended to categorize patients into groups that are clinically meaningful and
homogeneous with respect to resource use. Medicare's PPS currently uses 490
mutually exclusive DRGs, each of which is assigned a relative weight that
compares its costliness to the average for all DRGs (3M Health Information
Systems, 1995).
Disease Management - The integrated monitoring of a patient, particularly
with a chronic illness, to focus on prevention of recurrence, improved quality of
life, and cost-effective care. Also refers to the systematic study of a diagnosiS or
intervention to focus on the outcomes of a population, rather than an individual
patient.
ECMO - Extracorporeal membrane oxygenation (ECMO) is a life support
technique used for profound cardiorespiratory failure in infants who fail to
respond to conventional therapy. The infant's venous blood is pumped through a
membrane oxygenator (artificial lung) whereby oxygen is added and carbon
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dioxide is removed. The blood is then pumped back into the patient's venous or
arterial circulation. The procedure allows the lungs to rest and averts continuous
high-pressure mechanical ventilation in severe respiratory failure (Kanto, 1994).
Evidence-Based Medicine (EBM) - The conscientious, explicit and
judicious use of current best evidence in making decisions about the care of
individual patients (Field & Lohr, 1990; Sackett & Guyatt, 1992).
Gestational Age - The age of the infant based upon the date of the
mother's last menstrual period. Gestational age is classified as (a) preterm Less than 37 weeks, (b) term - 37 to 41 and 6/7 weeks, and (c) postterm - 42
weeks or more.
Infant - An infant is a live born fetus from time of birth through the
completion of one year of age (Committee on Perinatal Health, 1976).
Intermediate Care Nursery (ICN) - An ICN is a specialized nursery that
provides skilled care for premature infants and newborns.
International Classification of Diseases, Ninth Revision, Clinical
Modification (ICD-9-CM) - A diagnosis and procedure classification system
designed to facilitate the collection of uniform and comparable health information.
ICD-9-CM was issued in 1979 and is updated periodically. This system is used
to group patients into DRGs.
Length of Stay (LOS) - Length of stay in the NICU is defined as the date
of discharge - the date of admission.
Levell Nursery - No NICU, caring only for healthy infants.
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Level II Nursery - An Intermediate NICU, caring for moderately sick
infants. Most often with an average daily census of < 10 -13 patients.
Level 11(+) Nursery - Community NICUs providing many but not all
services of a level III regional tertiary care NICU facility. Small units have an
average daily census <15 patients while large units have an average daily
census of 15 or greater patients.
Level III Nursery - Regional or tertiary care NICU, providing a full range of
NICU services, including pediatric subspecialty consultations and surgery. These
units typically have an average daily census of 15 or greater.
Managed Care - A system that manages or controls what it spends on
health care by closely monitoring how physicians and other medical
professionals treat patients. Various techniques for keeping costs down include
limiting coverage to care provided by specially selected doctors and hospitals
and requiring preauthorization for hospital care and other services. Managed
care describes a collection of health plan activities designed to reduce the high
levels of utilization and spending that accompany unfettered fee-for-service
health care (Baker & Phibbs, 2002).
Medical Standards of Care - Known practices that are medically
necessary and services that any health care practitioner under any circumstance
would be required to render (Havighurst, Hutt, McNeil, & Miller, 2001).
Neonate - an infant born at less than 38 weeks gestation, or an infant
greater than 38 weeks gestation that requires hospitalization in a NICU.
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Neonatal Intensive Care Unit (NICU) - The NICU is a specialized nursery
that provides highly skilled care for premature or sick newborns. For this study,
Neonatal Intensive Care Unit (NICU) is defined as a specialized nursery that
provides highly skilled services for very low birthweight (VLBW) and low
birthweight (LBW), and medically fragile newborn infants.
Prospective Payment System (PPS) - Medicare's acute care payment
method for inpatient care. Prospective payment rates are set at a level intended
to cover operating costs for treating a typical inpatient in a given diagnosisrelated group. Payments for each hospital are adjusted for differences in area
wages, teaching activity, care to the poor, and other factors. Hospitals may also
receive additional payments to cover extra costs associated with atypical patients
(outliers) in each DRG.
Utilization Review (UR) - The review of services delivered by a health
care provider to evaluate appropriateness, necessity, and quality of the
prescribed services. The review can be performed on a prospective, concurrent,
or retrospective basis.
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Appendix 8
Systematic Care Management Process

ParadigmHealth's management process has the capability to scientifically refine
care processes over time by repeatedly examining the relationships between
process and outcome, eliminating inappropriate services, and enhancing both the
efficiency and the outcome of the care that is delivered.

Data
Collection and
Assessment

I
I
I
I
I
I
1_ _ -

Case
Conceptualization

Clinical Record
Review

Review Clinical
Risks
And Problems

Risk Factors
Identified

Profile Case Using
Paradigm Database

Family and
Support
System
Evaluated

Assess Provider
Network

ParadigmHealth
Medical Director
consults with
attending physician,
if necessary

Paradigm Health
Clinical Team
continues to manage
continuum of care

Develop Outcome
Plan

A
I

Provider Network
Nurse & Physician
..

l
I

___ J

Scientific Protocols
Database Analysis

Management Process Overview:
• Apply evidence-based standards of care
• Identify and manage deviations from predetermined pathway
• Delineation and management of specific problems and risks
• Expert peer-to-peer management
.
7
• Repeated examination of process and outcome using scien tific evidence
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Appendix C
Definition of Tier Groups and APR-DRG Assignments

Each tier is based upon the clinical resources required to ensure high quality and
effective medical services are provided to the Member and are ordered by
birthweight APR-DRG

640-1,2,3
636-1,2,3
632-1,2,3
625-1,2,3
621-1,2,3

639-1,2,3
635-1,2,3
631-1,2,3
624-1,2,3
620-1,2,3

638-1,2,3
634-1,2,3
630-1,2,3
623-1,2,3

637-1,2,3
633-1,2,3
626-1,2,3
622-1,2,3

1000 to 1999 614-1,2,3
Grams
610-1,2,3

613-1,2,3

612-1,2,3

611-1,2,3

602-1,2

601-1,2

600-1,2

> 1999
Grams

II

603-1,2

III

< 1000
Grams

IV

Complex
Conditions
and
Congenital
Anomalies

593-1,2,3,4
590-1,2,3,4
640-4
635-4
630-4
622-4
612-4
603-3,4

592-1 ,2,3,4
639-4
634-4
626-4
621-4
611-4
602-3,4

591-1,2,3,4

638-4
633-4
625-4
620-4
610-4
601-3,4

583-1,2,3,4
582-1 ,2,3,4

1

637-4
632-4
624-4
614-4

600-3,4

636-4
631-4
623-4
613-4
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Appendix D
Expected Birth Weights

The (5dh Percentile) at 24 - 28 Weeks' Gestation (Battaglia, 1967)
Gestational Age

Birth Weight (grams)

24

700

26

900

28

1100

30

1350

32

1650

34

2100

36

2600

38

3000

